

A multinational Delphi consensus to end the COVID-19 public health threat

Lazarus, Jeffrey V.; Romero, Diana; Kopka, Christopher J.; Karim, Salim Abdool; Abu-Raddad, Laith J.; Almeida, Gisele; Baptista-Leite, Ricardo; Barocas, Joshua A.; Barreto, Mauricio L.; Bar-Yam, Yaneer; ...

Source / Izvornik: **Nature**, 2022, 611, 332 - 345

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1038/s41586-022-05398-2>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:609302>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-06-30**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



A multinational Delphi consensus to end the COVID-19 public health threat

<https://doi.org/10.1038/s41586-022-05398-2>

Received: 19 May 2022

Accepted: 29 September 2022

Published online: 3 November 2022

Open access

 Check for updates

Jeffrey V. Lazarus^{1,2,3}✉, Diana Romero³, Christopher J. Kopka⁴, Salim Abdool Karim^{5,6}, Laith J. Abu-Raddad^{7,8}, Gisele Almeida⁹, Ricardo Baptista-Leite^{10,11,12}, Joshua A. Barocas¹³, Mauricio L. Barreto^{14,15}, Yaneer Bar-Yam¹⁶, Quique Bassat^{1,17,18,19,20}, Carolina Batista^{21,22}, Morgan Bazilian²³, Shu-Ti Chiou²⁴, Carlos del Rio²⁵, Gregory J. Dore²⁶, George F. Gao²⁷, Lawrence O. Gostin²⁸, Margaret Hellard²⁹, Jose L. Jimenez^{30,31}, Gagandeep Kang³², Nancy Lee³³, Mojca Maticic^{34,35}, Martin McKee³⁶, Sabin Nsanzimana³⁷, Miquel Oliu-Barton³⁸, Bary Pradelski³⁹, Oksana Pyzik⁴⁰, Kenneth Rabin³, Sunil Raina⁴¹, Sabina Faiz Rashid⁴², Magdalena Rathe⁴³, Rocio Saenz⁴⁴, Sudhvir Singh⁴⁵, Malene Trock-Hempler⁴⁶, Sonia Villapol⁴⁷, Peiling Yap⁴⁸, Agnes Binagwaho⁴⁹, Adeeba Kamarulzaman⁵⁰, Ayman El-Mohandes³ & The COVID-19 Consensus Statement Panel*

Despite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic^{1,2}. Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel of 386 academic, health, non-governmental organization, government and other experts in COVID-19 response from 112 countries and territories to recommend specific actions to end this persistent global threat to public health. The panel developed a set of 41 consensus statements and 57 recommendations to governments, health systems, industry and other key stakeholders across six domains: communication; health systems; vaccination; prevention; treatment and care; and inequities. In the wake of nearly three years of fragmented global and national responses, it is instructive to note that three of the highest-ranked recommendations call for the adoption of whole-of-society and whole-of-government approaches¹, while maintaining proven prevention measures using a vaccines-plus approach² that employs a range of public health and financial support measures to complement vaccination. Other recommendations with at least 99% combined agreement advise governments and other stakeholders to improve communication, rebuild public trust and engage communities³ in the management of pandemic responses. The findings of the study, which have been further endorsed by 184 organizations globally, include points of unanimous agreement, as well as six recommendations with >5% disagreement, that provide health and social policy actions to address inadequacies in the pandemic response and help to bring this public health threat to an end.

Pandemics have disrupted societies and impacted public health throughout human history⁴. Today, almost 3 years after SARS-CoV-2 was first identified and more than 1.5 years after the first vaccines became available, pandemic fatigue⁵ threatens to undercut our vigilance and the effectiveness of our responses to ongoing and new pandemic-related challenges. As of September 2022, more than 620 million cases of COVID-19 and over 6.5 million deaths have been reported⁶, although mortality estimates range as high as 20 million^{7,8}. The healthcare for millions more people has been delayed, often as a result of overwhelmed health systems^{9–12}. Highly transmissible variants continue to spread globally, while surveillance for variants of concern remains largely inadequate^{13–15}. Reinfection risks are not fully understood. Low vaccination rates¹⁶ may compound the risk from waning immunity^{17,18}. Long COVID has emerged as a serious chronic condition^{19–21} that represents

a considerable burden of disease and still lacks adequate understanding and appropriate preventive or curative solutions. In addition to its direct health consequences, COVID-19 has disrupted economic activity, social interactions and political processes, affected civil liberties and interrupted education at all levels^{22–26}. Although many governments and individuals no longer have the same level of concern as earlier in the pandemic²⁷, many public health leaders, including members of this panel²⁸, continue to regard COVID-19 as a persistent and dangerous health threat^{29–31}.

Responses to the COVID-19 pandemic have been hindered by inter-related factors that include false information³², vaccine hesitancy^{33,34}, inconsistent global coordination³⁵, and the inequitable distribution of supplies³⁶, vaccines^{37,38} and treatments³⁹. Despite increased levels of trust in science during the pandemic^{23,40}, there is information

A list of affiliations appears at the end of the paper.

fatigue⁴ and waning compliance with those public health and social measures^{41–43} that remain in place, particularly those that affect daily lives⁴⁴. Meanwhile, during periods of high community transmission, needs for services continue to exceed the capacity of many health systems⁴⁵, which also are challenged by ongoing risks to the health of their workers^{46–48}. Furthermore, long-standing social inequities have caused some populations to experience greater risk of COVID-19 infection, severe disease and death³⁷. Many of these populations continue to have less access to COVID-19 vaccines^{37,49} and treatment³⁹, as well as to resources to mitigate the mental health, social and economic consequences of the pandemic^{50–52}.

Beneficial knowledge about COVID-19 aetiology, pathophysiology, prevention, vaccination, treatment and care has rapidly advanced through rigorous scientific, medical and public health inquiry, debate and collaboration^{53–56}. Notwithstanding these advances, the responses of individual countries have been heterogeneous and often inadequate, in part because they lack coordination and clear goals.

To develop a global consensus regarding these ongoing problems, we carried out a Delphi study with a multidisciplinary, geographically diverse panel of 386 academic, health, non-governmental organization (NGO), government and other experts in COVID-19 response from 112 countries and territories (Table 1 and Methods). We achieved response rates of 85% in the second round (R2) and 82% and 81% in the third round (R3) surveys of the 41 statements and 57 recommendations, respectively. The mean levels of combined agreement (agree + somewhat agree) increased across the three rounds of the consensus statements (R1, 89%; R2, 90%; R3, 96%) and the two rounds of recommendations (R2, 93%; R3, 98%). The resulting consensus statements and recommendations (Fig. 1) can serve as a strong basis for decision-making to end COVID-19 as a public health threat, and permit a more durable resumption of social, cultural, religious, political, healthcare, economic and educational activities, with less burden on vulnerable populations.

Top-ranked consensus recommendations

This multidisciplinary and multinational consensus study yielded 41 statements (Tables 2 and 3) and 57 forward-looking recommendations (Tables 4–7) on ending COVID-19 as a threat to public health grouped into six domains. Although we suggest that policymakers and other interested stakeholders review and consider the entire study findings, for expediency, we break out the top 10 recommendations ranked by the panellists in Table 8.

The top three recommendations focus on whole-of-society¹ action and maintaining, or in some cases returning, to a vaccines-plus approach². First, to avoid the inefficiency and ineffectiveness of fragmented efforts, pandemic preparedness and response should adopt a whole-of-society strategy that includes multiple disciplines, sectors and actors. Second, going forward, whole-of-government approaches (such as interministry coordination) can identify, review and address resilience in health systems to make them more responsive to people's needs. Third, all countries should adopt a vaccines-plus approach, which includes a combination of COVID-19 vaccination, other prevention measures, treatment and financial incentives such as support measures. Infection rates tend to increase when governments discontinue social measures, including non-pharmaceutical interventions, regardless of the level of vaccination^{57,58}.

The degree of consensus achieved for statements and recommendations, along with a ranking exercise in the final round, informed our synthesis of the study's findings into six cross-cutting themes (Box 1) to which we believe decision-makers should pay particular attention: (1) SARS-CoV-2 is still present among us—despite some governments moving on—requiring continued efforts and resources to save lives; (2) vaccines are an effective tool against COVID-19 but will not alone end COVID-19 as a public health threat; (3) multisectoral collaboration

Table 1 | Expert panel characteristics (n=386)

Characteristic	n (%)
Gender	
Man	225 (58)
Woman	155 (40)
No response	6 (2)
Primary sector of employment^a	
Civil society	254 (66)
Private	61 (16)
Academic	39 (10)
Public	21 (5)
Other	6 (2)
No response	5 (1)
Primary field^b	
Public health	156 (41)
Clinical research/care	92 (24)
Health policy/advocacy	67 (17)
Basic/physical/mathematical sciences	41 (11)
Other	24 (6)
No response	6 (2)
Country income level^c	
Low- or middle-income country	195 (51)
High-income country	186 (48)
No response	5 (1)
Global region of origin^c	
Europe and Central Asia	117 (30)
Latin America and Caribbean	56 (15)
East Asia and Pacific	49 (13)
North America	47 (12)
Sub-Saharan Africa	44 (11)
Middle East and North Africa	33 (9)
South Asia	35 (9)
No response	5 (1)

Percentages may not sum to 100 owing to rounding.

^aPanellists were provided with these four standard categories for public health sectors and were able to provide a different response with the 'other' option.

^bPanellists were provided with six response options (clinical research, public health research, healthcare provider, advocacy, health department or ministry and health policy) and 'other'. The text responses under the 'other' option (n=76) were analysed and recategorized into the four categories reported in the table.

^cCountry income level and global region correspond to World Bank classification for 2022 (<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>).

that centres on communities and fosters trust is needed; (4) responsive health systems are crucial for responding to the COVID-19 pandemic and require coordinated government support; (5) adverse forces challenge efforts to end the COVID-19 public health threat; and (6) none of us is safe until everyone is safe. For ease of review, we report the tophalf ranked recommendations within each domain (Extended Data Fig. 1).

Areas of less agreement

The Delphi process involves a review and revision methodology that can result in relatively greater agreement among statements and recommendations over successive survey rounds while also identifying areas of disagreement that may require special efforts going forward. In addition to its the four-point Likert agreement–disagreement response options available in this study, panellists could select 'not qualified to




Fig. 1 | Delphi panel generation and data collection. Study methodology, including sample and data collection. Top, the iterative sampling approach used to generate a large, diverse Delphi panel ($n = 386$): four project co-chairs identified a core group of 40 academic, health, NGO, government and policy experts from 25 countries; the core group identified individuals with expertise in COVID-19; under-represented countries (that is, with fewer than one invitee) were identified and targeted through PubMed/Medline searches for authors of COVID-19 research studies in these countries. Bottom, the iterative digital data-collection process, including two survey rounds (R1 and R2) of draft

statements; an online consensus meeting of the core group (Supplementary Discussion 3); one round of draft recommendations (R2); and a final survey round (R3) of the consensus statements and recommendations. Earlier rounds included text boxes for panellists to provide comments and suggest edits to individual statements (R1, R2) and recommendations (R2); the final statement and recommendations round (R3) allowed for overall comments at the end of each domain. For the final set of recommendations in R3, panellists ranked the top half in each of the six domains. RR, response rate.

respond' for items that they perceived as falling outside their expertise (see the 'Delphi expert panel member sample' section in the Methods). Although our study reflects relatively few areas of disagreement, we believe that highlighting the key areas of disagreement may be instructive for decision-makers in their own prioritization processes addressing the COVID-19 pandemic.

Extended Data Table 1 presents the six recommendations reflecting 5% or greater disagreement (disagree + somewhat disagree). Of those six, only two recommendations had greater than 10% disagreement: 18% of panellists disagreed with the recommendation to consider further economic incentives to potentially address vaccine hesitancy (REC3.6) and 11% disagreed with the recommendation that providers adopt a syndromic approach to COVID-19 diagnosis in settings with lower access to testing (REC2.18). The remaining four recommendations broadly relate to the use of governmental regulatory and enforcement powers in disease control efforts.

For statements and recommendations with response rates of 'agree' alone (that is, not combined with 'somewhat agree') below 67%, we conducted bivariate analyses to examine potential associations with panellist demographics; six statements (STMT1.2, STMT1.3, STMT2.1, STMT2.3, STMT3.5, STMT6.6) and one recommendation (REC4.5) demonstrated significant differences. Respondents who disagreed were significantly more likely to work in low- and middle-income countries than in high-income countries ($P < 0.05$; Supplementary Discussion 2). Few differences in agreement were identified by sector or field of employment, except for STMT1.1, for which greater disagreement was identified among those working in the health policy/advocacy field, and for STMT1.3, for which the academic and public sectors evidenced greater disagreement than other sectors.

Key statements and recommendations

The following six domains summarize the main areas of agreement, with particular focus on the recommendations. The quantitative results on agreement and disagreement for the statements and recommendations are reflected in the tables and are further illustrated in Supplementary Discussion 1.

Communicate effectively

Substantial combined agreement among the panellists (range, 88–100%) indicates that communication issues remain a key area of risk and opportunity for ending COVID-19 as a public health threat. Policymakers and public health agencies should take special care when communicating the causation of and continuing accountability for the pandemic (Tables 2 (STMT1.7) and 4 (REC1.1)). The lowest level of agreement in this domain (agree, 57%; combined agreement, 88%) was found for a statement about government accountability receiving less attention when unvaccinated individuals are blamed for the pandemic's continuation (Table 2 (STMT1.6)).

The panel focused primarily on the role of trust in government (Table 2 (STMT1.5)), the consequences of false information (Table 2 (STMT1.2, STMT1.3, STMT1.4)) and the rapid production of large volumes of new COVID-19-related information (Table 2 (STMT1.1)). That said, governments themselves may be a source of misinformation, for example, in the context of identifying transmission mechanisms (Table 6 (REC4.3)) and when stating that the COVID-19 pandemic has ended (Table 2 (STMT1.7)).

To counteract the infodemic and false information, governments should monitor false information (Table 4 (REC1.7)), expose networks of false information (Table 4 (REC1.9)) and consider holding publishers of false information liable (Table 4 (REC1.10)). Furthermore, public health professionals and other authorities should use clear, culturally responsive messaging to combat false information (Table 4 (REC1.3)). In parallel, social media companies should implement controls that reduce the publication and dissemination of false health information (Table 4 (REC1.8)).

Institutions and individuals should advance public trust by seeking training on building trust and developing trust-oriented communication strategies (Table 4 (REC1.4)), expanding collaboration with community leaders and the scientific community (Table 4 (REC1.1)), and working with individuals and organizations that have established trust in communities (Table 4 (REC1.2)). Using the preferred means of communication for different populations was unanimously recommended to further earn trust (Table 4 (REC1.1)).

Table 2 | Consensus statements to end COVID-19 as a public health threat

Statement	Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)
Communication							
STMT1.1 The volume and velocity of information during the COVID-19 pandemic have made it difficult for people to assess the accuracy of information.	A	81	19	0	1	316	0
STMT1.2 Public health authorities contribute to the dissemination of false information when their communications do not reflect current scientific understanding that transmission of SARS-CoV-2 is primarily airborne.	A	68	24	6	3	313	1
STMT1.3 Governments have inconsistently counteracted false information in the context of the COVID-19 pandemic.	A	70	23	4	3	312	1
STMT1.4 Sources of false information undermine the social cohesion needed for an effective public health response.	A	91	8	1	0*	316	0
STMT1.5 During the pandemic, public health officials have ineffectively engaged populations that have low levels of trust in government.	A	69	25	4	1	312	1
STMT1.6 Blaming unvaccinated individuals for continuation of the pandemic shifts attention away from government accountability.	B	57	31	8	4	307	3
STMT1.7 A government's decision to reduce COVID-19 pandemic control measures does not mean that the threat to public health has ended.	A	94	5	1	0	315	0
Health systems							
STMT2.1 The world has not implemented an evidence-based, globally agreed-upon set of minimum COVID-19 pandemic response standards addressing monitoring, prevention, treatment and care.	A	73	18	6	3	309	1
STMT2.2 There continue to be systemic risks of COVID-19 infection for healthcare workers in many healthcare settings.	A	82	16	2	1	306	2
STMT2.3 Health systems are continuing to face abnormal staffing shortages due to the mental and physical health impacts on their workers from the COVID-19 pandemic.	A	79	16	4	0	305	3
STMT2.4 Healthcare workers continue to experience unaddressed mental health issues due to the pandemic.	A	81	17	2	0	296	5
STMT2.5 Governments have not always addressed the high out-of-pocket expenditure to consumers for some pandemic control measures (for example, testing) and personal protective equipment (for example, facemasks).	A	78	17	3	2	310	1
STMT2.6 The COVID-19 pandemic continues to reveal vulnerabilities in the global supply-chain framework for essential public health supplies.	A	91	8	1	0*	306	2
STMT2.7 The COVID-19 pandemic has catalysed opportunities for rapid innovation in digital health solutions throughout the care continuum.	A	84	14	1	1	308	1
STMT2.8 Leveraging economies of scale and scope through multicountry pooled procurement can enable health systems to increase access to essential medicines and supplies during public health crises.	A	85	14	1	1	305	2
STMT2.9 Community-based interventions and services to address the pandemic continue to be underused by health systems.	A	79	19	2	0*	302	4
Vaccination							
STMT3.1 When the risk of harm to others is sufficiently severe, governments may determine that the right of all individuals to good health overrides the autonomy of any one individual to choose not to be vaccinated.	A	68	24	5	4	309	1
STMT3.2 Individual medical autonomy acknowledges that individuals who have decision-making capacity have the right to make decisions regarding vaccination, even when their decisions contradict their healthcare providers' recommendations.	B	59	25	8	8	306	2
STMT3.3 Vaccine hesitancy, which ranges from delay to refusal despite the availability of vaccine services, remains a major challenge to ending the COVID-19 pandemic as a public health threat.	A	75	21	3	1	309	1
STMT3.4 Discussing vaccine hesitancy as primarily a function of information or worldview is inaccurate, as vaccine hesitancy is a multifactorial phenomenon comprising other factors (for example, socioeconomic).	A	82	12	3	2	308	1
STMT3.5 Continued low levels of trust in information from government sources are associated with vaccine hesitancy.	A	78	17	4	2	309	1
STMT3.6 Vaccination alone is insufficient to end the COVID-19 pandemic as a public health threat.	A	83	14	3	1	311	0

Grades are based on the percentage of combined agreement (agree+somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each statement (STMT) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

Multidisciplinary research should assess the impact of the COVID-19 infodemic on health behaviours and outcomes (Table 4 (REC1.5)). Research funders should commission more reviews that synthesize, evaluate and disseminate COVID-19-related evidence to inform needed interventions (Table 4 (REC1.6)).

Strengthen health systems

Health systems have experienced wide-ranging circumstances throughout the pandemic, from periods of relative calm to periods of near collapse. The broad agreement among panellists strongly

Table 3 | Consensus statements to end COVID-19 as a public health threat

Statement	Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)
Prevention							
STMT4.1 SARS-CoV-2 is an airborne virus that presents the highest risk of transmission in indoor areas with poor ventilation.	A	92	8	0*	0*	311	0
STMT4.2 The assumption that endemicity automatically means that variants will have lower virulence is not scientifically sound and should not be a basis for public policy decision-making.	A	81	15	2	1	297	5
STMT4.3 SARS-CoV-2 mammal-to-mammal, outdoor transmission represents a reservoir for future zoonotic variants.	A	76	20	3	1	268	14
STMT4.4 Relying on individual, voluntary compliance with transmission prevention measures is insufficient to end COVID-19 as a public health threat.	A	81	15	3	1	311	0
STMT4.5 Infection rates tend to increase when governments discontinue social measures, including non-pharmaceutical interventions, regardless of the level of vaccination.	A	75	19	4	2	306	2
STMT4.6 Wide use of high-filtration and well-fitting facemasks (for example, N95, KF94, KN95, FFP2/3) is important to reduce transmission, particularly in high-risk settings.	A	87	9	3	1	307	1
STMT4.7 Most countries have not adequately protected children throughout the pandemic, that is, preventing SARS-CoV-2 transmission while simultaneously addressing their physical, mental and social well-being.	A	77	17	5	2	309	1
Treatment and care							
STMT5.1 Prioritizing the treatment of severe COVID-19 over the prevention of SARS-CoV-2 transmission risks increasing infections, long COVID and the overall burden of disease.	A	72	20	5	2	299	4
STMT5.2 More effective COVID-19 therapeutic options, as well as care delivery models, are needed.	A	91	8	1	0	303	3
STMT5.3 In addition to the standardized long COVID case definition for adults, a standardized definition is needed for children.	A	90	10	0*	0	298	4
STMT5.4 Research is needed to determine whether infection from distinct variants of SARS-CoV-2 is associated with significant differences in long-term morbidity.	A	91	8	1	0	305	2
Pandemic inequities							
STMT6.1 The COVID-19 pandemic disproportionately impacts the most vulnerable populations within communities, countries and globally.	A	92	6	1	1	311	0
STMT6.2 The decision by most high-income countries to protect intellectual property rights for COVID-19 vaccines and treatments has contributed to limited options available to low- and middle-income countries for addressing the pandemic.	A	83	11	4	3	304	3
STMT6.3 It is in the best interests of high-income countries to fund the equitable distribution of vaccines and treatments to low- and middle-income countries.	A	88	9	2	0*	308	1
STMT6.4 There is a disproportionate consumption of health system resources by those voluntarily unvaccinated.	A	65	25	7	3	295	5
STMT6.5 When expanding use of digital communications technology (for example, online appointment systems, mobile patient communications and telehealth applications) health systems may inadvertently contribute to inequitable access to healthcare services.	A	64	30	6	1	307	1
STMT6.6 The global pandemic response has generally not taken into account the underlying role of social determinants of health.	A	77	21	2	0*	308	1
STMT6.7 Few governments have adequately engaged vulnerable populations to inform pandemic response priorities.	A	78	17	4	0*	303	3
STMT6.8 The incorporation of research paradigms from diverse disciplines has greater potential to end COVID-19 as a public health threat than reliance on a single research paradigm (for example, evidence-based medicine).	A	88	9	2	1	309	1

Grades are based on the percentage of combined agreement (agree + somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each statement (STMT) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

suggests that, although many health systems will remain at risk of once again being overwhelmed, those risks can be mitigated. Certain sources of risk to health systems are essentially structural, such as the lack of implementation of an evidence-based, globally agreed-upon set of minimum COVID-19 pandemic response standards (Table 2 (STMT2.1)).

As noted above, health systems recommendations with respect to whole-of-society (Table 4 (REC2.5)) and whole-of-government approaches (for example, multiminsty coordination) (Table 4 (REC2.6)) were among the most highly ranked by the panel.

As community transmission of SARS-CoV-2 continues to present a risk to health systems, particularly through variants of concern, extensive virological surveillance should be used (Table 5 (REC2.8)). Public health

policies should take better account of the potential long-term impact of the unchecked spread of COVID-19 given the ongoing uncertainties about the prevalence, severity and duration of post-COVID-19 morbidity (long COVID) (Table 5 (REC2.9)). Member States should authorize the World Health Organization (WHO) to lead a large, inclusive, multi-stakeholder, global effort to provide public health and clinical targets pertaining to SARS-CoV-2 and COVID-19, with an emphasis on cases, vaccination, morbidity and mortality (Table 5 (REC2.17)).

Economic impacts, notably costs borne by consumers (Table 2 (STMT2.5)), create risks to health systems. To address these risks, structural and economic recommendations include removing economic barriers to SARS-CoV-2 tests, personal protective equipment, treatment and care (Table 4 (REC2.1)), supporting the development of

Table 4 | Recommendations to end COVID-19 as a public health threat

Recommendation	Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)	Rank
Communication								
REC1.1	U	96	4	0	0	312	0	1
REC1.2	A	95	5	0*	0	312	0	2
REC1.3	A	94	5	0*	0*	311	0	3
REC1.4	A	94	5	1	0	311	0	4
REC1.5	A	93	6	1	0*	311	0	
REC1.6	A	83	16	1	0*	309	0	
REC1.7	A	81	17	2	1	312	1	5
REC1.8	A	87	11	2	1	311	0	
REC1.9	A	80	17	2	1	310	1	
REC1.10	A	76	17	6	1	308	1	
Health systems								
REC2.1	A	90	10	0*	0	313	0	6
REC2.2	A	91	8	0	0*	308	2	5
REC2.3	A	86	13	0*	0*	313	0	
REC2.4	A	97	2	0	1	311	0	4
REC2.5	A	95	4	1	0	312	0	1
REC2.6	A	93	6	1	0	309	2	2

Grades are based on the percentage of combined agreement (agree + somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each recommendation (REC) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

regional manufacturing hubs for COVID-19 supplies, treatments and vaccines (Table 4 (REC2.2)), and considering legislative and regulatory reforms to address market failures (Table 5 (REC2.16)). Where access to PCR or antigen tests is limited, providers should consider adopting a syndromic approach (Table 5 (REC2.18)). Notably, REC2.18 is the health systems recommendation with the highest percentages of panellists disagreeing as well as panellists indicating ‘not qualified to respond’.

To reduce the burden on hospitals, the role of primary health care should be strengthened (Table 5 (REC2.10)), while health care workers’ physical, mental and social well-being should be supported (Table 4 (REC2.4)).

With respect to digital health, the recommendations encourage increasing investments in digital health infrastructure (Table 5 (REC2.13)),

adapting user interfaces and experience to expand access, particularly for vulnerable groups (Table 4 (REC2.3)), and leveraging implementation science to determine which digital health solutions can be quickly scaled (Table 5 (REC2.12)).

With respect to procurement practices, engaging continuous improvement disciplines for intercountry procurement, pooling and supply-chain management was urged (Table 5 (REC2.11)). To best leverage community-based interventions and services, community-based organizations and students pursuing degrees in health-related fields should be engaged in providing COVID-19 education, testing and vaccination services (Table 5 (REC2.14)).

As social, political and economic sector risks continue to have spillover effects on health systems, key multisectoral indicators for

Table 5 | Recommendations to end COVID-19 as a public health threat

Recommendation	Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)	Rank
Health systems								
REC2.7	A	92	7	1	0*	305	2	
REC2.8	A	86	13	1	0	287	8	
REC2.9	A	86	13	1	0*	310	1	
REC2.10	A	92	6	1	0*	310	1	3
REC2.11	A	91	7	2	0	301	4	8
REC2.12	A	85	13	2	0	300	4	
REC2.13	A	86	12	2	0	310	1	
REC2.14	A	77	20	3	0*	312	0	
REC2.15	A	88	9	1	3	305	3	
REC2.16	A	80	13	4	3	297	6	7
REC2.17	A	73	19	6	2	306	3	9
REC2.18	B	68	21	9	2	282	11	

Grades are based on the percentage of combined agreement (agree + somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each recommendation (REC) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

systemic risks to health systems should be identified and assessed (Table 5 (REC2.7)).

Finally, health systems should identify and, where possible, reduce diagnostic, treatment and care backlogs for non-COVID-19-related medical conditions (Table 5 (REC2.15)).

Emphasize vaccination, but not exclusively so

Even assuming continued innovation of vaccines and interventions that reduce vaccine hesitancy, 97% of the panel agrees that vaccination alone is insufficient to end the COVID-19 pandemic as a public health threat (Table 2 (STMT3.6)). Thus, the panel places a strong emphasis on additional prevention measures, particularly, as noted above and in the ten highest-ranked recommendations (Table 8), for countries to adopt a vaccines-plus approach, as discussed in the next domain.

Regarding the key role of vaccines, the panel made a range of recommendations. Government, philanthropic and industry funding should invest in developing vaccines that provide long-lasting protection against multiple SARS-CoV-2 variants (Table 6 (REC3.4)). As waning immunity remains a risk, calculations for immunity should consider

the time after the date of vaccination and/or infection and be regularly updated with new scientific evidence (Table 6 (REC3.5)).

Vaccine hesitancy, which ranges from delay to refusal despite availability of vaccine services, remains a major challenge (Table 2 (STMT3.3)). To reduce vaccine hesitancy and increase uptake, several interventions are recommended: engaging trusted local leaders and organizations in vaccination efforts (Table 6 (REC3.2)), providing information that clearly explains the efficacy and limitations of current vaccines (Table 6 (REC3.1)) and tailoring messages to address the underlying bases of various populations’ specific concerns through targeted public health communications (Table 6 (REC3.3)). Vaccine hesitancy may also be associated with false information, which is addressed in the communication domain above.

On the one hand, panellists largely agree that medical autonomy of individuals with decision-making ability extends to the right to make one’s own decisions regarding vaccination (Table 2 (STMT3.2)). On the other hand, panellists also acknowledge that, when the risk of harm to others is sufficiently severe, governments may determine that the right of all individuals to good health overrides the autonomy of any one individual to choose not to be vaccinated (Table 2 (STMT3.1)). These statements

Table 6 | Recommendations to end COVID-19 as a public health threat

Recommendation	Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)	Rank	
Vaccination									
REC3.1	Vaccination messaging should clearly explain the efficacy and limitations of current vaccines in preventing SARS-CoV-2 transmission and reducing the severity of COVID-19.	A	93	7	0*	0*	312	0	2
REC3.2	In settings where individuals have lower levels of trust in government, vaccination efforts should engage trusted local leaders and organizations.	A	93	6	1	0	311	0	
REC3.3	To combat vaccine hesitancy, tailored messages that address the underlying bases of an individual's concerns should be used in targeted public health communications.	A	93	6	1	0	310	1	3
REC3.4	Government, philanthropic and industry funding should include a focus on developing vaccines that provide long-lasting protection against multiple SARS-CoV-2 variants.	A	90	9	1	0	309	1	1
REC3.5	Calculations for immunity should take into consideration the time following the date of vaccination and/or infection and be regularly updated with new scientific evidence.	A	93	4	2	1	398	4	
REC3.6	As the causes of vaccine hesitancy are not solely a function of information or worldview, economic incentives should be considered in parallel with information and access to increase vaccination rates.	B	57	25	13	5	303	3	
Prevention									
REC4.1	Governments should regulate and incentivize the development and deployment of structural prevention measures (for example, ventilation, air filtration) to mitigate airborne transmission of SARS-CoV-2, with an early emphasis on high-risk settings.	A	86	12	1	0	307	0	
REC4.2	Measures that are no longer scientifically valid for COVID-19 prevention should be immediately removed from COVID-19 guidance and policy.	A	88	10	2	0	307	0	
REC4.3	Risk communications should clearly emphasize that transmission of SARS-CoV-2 is primarily caused by inhalation of the virus.	A	90	8	2	0	302	1	
REC4.4	National and international travel restrictions should be based on current scientific knowledge and prevailing transmission rates of all variants that take into account relevant, health-based factors (for example, traveller's vaccination status, proof of recent recuperation from COVID-19 or a negative result of an antigen or PCR test).	A	85	12	1	2	305	0	
REC4.5	All countries should adopt a vaccines-plus approach that includes a combination of COVID-19 vaccination, prevention measures, treatment and financial incentives.	A	82	14	4	0	307	0	1
REC4.6	Prevention of SARS-CoV-2 transmission in the workplace, educational institutions and centres of commerce should remain a high priority, reflected in public health guidance and supported through multiple social measures and structural interventions (for example, remote work/schooling policies, ventilation, air filtration, facemask wearing).	A	85	11	3	1	307	0	2
REC4.7	Governments should consider imposing broad restrictions on civil liberties only in the event of variants of concern presenting risk of high rates of transmission and severity, coupled with (1) waning immunity or (2) vaccine resistance.	A	71	21	5	3	305	0	3

Grades are based on the percentage of combined agreement (agree + somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each recommendation (REC) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

reflect among the highest levels of combined disagreement (Table 2 (STMT3.1, 9%; STMT3.2, 16%)). Civil liberties implications are further discussed in the next domain.

Promote preventive behaviours

As noted above, vaccination alone will not end COVID-19 as a public health threat (Table 2 (STMT3.6)) for all people. Infection rates tend to increase when governments discontinue social measures, including non-pharmaceutical interventions, regardless of the level of vaccination (Table 3 (STMT4.5)). Thus, all countries should adopt a vaccines-plus approach, including a combination of COVID-19 vaccination, other prevention measures, treatment and possibly financial incentives (Table 6 (REC4.5)).

Although the nature and vectors of SARS-CoV-2 transmission were not clearly understood early in the pandemic, current evidence guided the panellists to near-unanimous agreement that SARS-CoV-2 is an airborne virus that presents the highest risk of transmission in indoor areas with poor ventilation (Table 3 (STMT4.1)). Risk-related communications from all actors should clearly emphasize that transmission of SARS-CoV-2 is primarily caused by inhalation of the virus (Table 6

(REC4.3)). Considering the airborne nature of transmission, governments should regulate and incentivise structural prevention measures, such as ventilation and air filtration (Table 6 (REC4.1)), and high priority should be given to preventing SARS-CoV-2 transmission in the workplace, educational institutions and commercial centres (Table 6 (REC4.6)).

Mammal-to-mammal transmission represents a reservoir for future zoonotic variants (Table 3 (STMT4.3)). Thus, substantial virological surveillance based on whole-genome sequencing of positive samples in human and high-risk mammal populations is an essential component of the continued pandemic response and preparedness (Table 5 (REC2.8)).

National and international travel restrictions should be based on current scientific knowledge and prevailing transmission rates of all variants that consider relevant, health-based factors (Table 6 (REC4.4)). Measures that are no longer scientifically valid for COVID-19 prevention should be immediately removed from COVID-19 guidance and policy (Table 6 (REC4.2)). Going forward, governments should consider imposing broad restrictions on civil liberties only in the event of variants of concern presenting risk of high rates of transmission and severity, coupled with waning immunity or vaccine resistance (Table 6 (REC4.7)).

Table 7 | Recommendations to end COVID-19 as a public health threat

Recommendation		Grade	A (%)	SA (%)	SD (%)	D (%)	N (%)	NQ (%)	Rank
Treatment and care									
REC5.1	Global case definitions for SARS-CoV-2 and for COVID-19 morbidity and mortality should be standardized.	U	92	8	0	0	305	0	3
REC5.2	Promote multisectoral collaboration to accelerate the development of new therapies for all stages of COVID-19 (for example, outpatient, hospitalization and long COVID).	A	95	5	0	0*	309	1	1
REC5.3	Clinical trials and longitudinal cohorts should include statistically sufficient samples from all age groups, genders and vulnerable populations.	A	93	7	0*	0	306	1	
REC5.4	Expand the evidence base on the cumulative effect of COVID-19 reinfection to inform public health policy.	A	90	9	1	0*	308	1	
REC5.5	Governments should now prioritize early case detection so that health systems can facilitate earlier treatment and care.	A	80	17	1	1	304	1	
REC5.6	Prioritize research funding for long COVID to develop diagnostic tools, treatment and care, and knowledge about extrinsic factors (for example, stigma and discrimination).	A	85	12	3	0	306	0	2
Pandemic inequities									
REC6.1	Recognizing that local and regional contexts are important for equitable responses to the pandemic, governments should engage communities and multidisciplinary experts who understand the local context when developing operational plans for ending COVID-19 as a public health threat.	A	95	5	0*	0	311	0	3
REC6.2	In addition to current vaccine equity efforts, governments and global health organizations should better coordinate to make COVID-19 tests and treatments affordable for all people in all countries.	A	93	6	0*	0	310	0	4
REC6.3	Decision-making bodies (for example, governments, WHO committees) should meaningfully and transparently engage with a broad base of voices to inform their decisions.	A	93	6	0*	0	311	0	
REC6.4	Governments, regional bodies, industry and health systems should anticipate the procurement and supply management needs for supplies, treatments and vaccines in low-resource settings (for example, transportation logistics, storage, refrigeration).	A	93	6	0*	0*	306	2	
REC6.5	Pandemic preparedness, response planning and policy should be reviewed and updated to protect children, emphasizing the prevention of SARS-CoV-2 transmission while simultaneously addressing their physical, mental and social well-being.	A	90	9	0*	1	309	0	
REC6.6	Global trade and health organizations should coordinate with countries to negotiate the transfer of technologies enabling manufacturers in low- and middle-income countries to develop quality assured and affordable vaccines, tests and therapeutics.	A	95	4	1	0*	307	2	2
REC6.7	Pandemic preparedness and response should address pre-existing social and health inequities.	A	94	5	1	0*	307	1	1
REC6.8	Governments, industry and health systems should prioritize minimizing closed- and open-vial vaccine wastage, with an early emphasis on wastage resulting from unnecessarily short expiration dates, and by addressing regulatory barriers and procurement and supply management challenges for transferring or donating vaccine doses.	A	86	13	1	0	301	3	
REC6.9	Pandemic preparedness and response efforts should assess and mitigate the risks and effects of SARS-CoV-2 transmission among people within and emigrating from conflict zones.	A	86	13	2	0		1	
REC6.10	High-income countries should refocus the distribution of vaccines to countries with low rates of vaccination and inadequate access to vaccines.	A	86	12	2	0*		0	5

Grades are based on the percentage of combined agreement (agree + somewhat agree). U, unanimous (100%) agreement; A, 90%–99% agreement; B, 78%–89% agreement; C, 67%–77% agreement. Responses to each recommendation (REC) are presented as percentages of the total responses. A, agree; SA, somewhat agree; SD, somewhat disagree; D, disagree; N, total number of responses; NQ, the number of participants that indicated that they were not qualified to respond. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

Expand treatments

Panellists had substantially high agreement regarding all aspects of treatment and care, indicating that treatment will continue to be an area of major importance both for ending COVID-19 as a public health threat and for individual patient care. Notably, a statement addressing the risk of prioritizing treatment over prevention (Table 3 (STMT5.1)) had the highest level of combined disagreement (7%) for this domain.

With current public health policies reflecting greater tolerance for community transmission and increased rates of infection, research into

COVID-19 must adapt and develop further evidence to understand the cumulative effect of COVID reinfection (Table 7 (REC5.4)). Research is needed to determine whether infection from distinct variants of SARS-CoV-2 is associated with significant differences in long-term morbidity (Table 3 (STMT5.4)). Additional research funding, particularly for long COVID, should be prioritized (Table 7 (REC5.6)), and multisectoral collaboration should accelerate new therapies across all stages of COVID-19 (Table 7 (REC5.2)). Moreover, global case definitions should be standardized (Table 7 (REC5.1)).

Echoing some statements and recommendations in the pandemic inequities domain (discussed below), clinical trials and longitudinal

Table 8 | Ten highest ranked recommendations

Rank	Domain	Recommendation	Disagreement (SD+D) (%)
1	Health systems	Pandemic preparedness and response planning should adopt a whole-of-society approach that includes multiple disciplines, sectors and actors (for example, business, civil society, engineering, faith communities, mathematical modelling, military, media and psychology).	1
2	Communication	Community leaders, scientific experts and public health authorities should collaborate to develop public health messages that build and enhance individual and community trust and use the preferred means of access and communication for different populations.	0
3	Prevention	All countries should adopt a vaccines-plus approach that includes a combination of COVID-19 vaccination, prevention measures, treatment and financial incentives.	4
4	Pandemic inequities	Pandemic preparedness and response should address pre-existing social and health inequities.	1
5	Communication	Public health authorities should partner with individuals and organizations that are trusted within their communities to provide accurate, accessible information about the pandemic and inform behaviour change.	0*
6	Vaccination	Government, philanthropic and industry funding should include a focus on developing vaccines that provide long-lasting protection against multiple SARS-CoV-2 variants.	1
7	Communication	Public health professionals and authorities should combat false information proactively based on clear, direct, culturally responsive messaging that is free of unnecessary scientific jargon.	1
8	Health systems	Preparedness and response strategies should adopt whole-of-government approaches (for example, multimilitary coordination) to identify, review and address resilience in health systems.	1
9	Pandemic inequities	Global trade and health organizations should coordinate with countries to negotiate the transfer of technologies enabling manufacturers in low- and middle-income countries to develop quality assured and affordable vaccines, tests and therapeutics.	1
10	Treatment and care	Promote multisectoral collaboration to accelerate the development of new therapies for all stages of COVID-19 (for example, outpatient, hospitalization and long COVID).	0*

SD+D, the combined percentage of 'somewhat disagree' and 'disagree' responses. The asterisks indicate that rounding resulted in 0% despite the presence of ≥1 response in the disagreement category.

cohorts should be more inclusive and statistically representative regarding age, gender and vulnerable populations (Table 7 (REC5.3)).

Eliminate inequities

The substantial agreement of the panellists suggests that addressing inequities remains a global challenge. Immediate efforts should be made to reduce vaccine wastage (Table 7 (REC6.8)), addressing the need for cold storage, transport and other infrastructure-based barriers in low-resource settings (Table 7 (REC6.4)), addressing the affordability of testing and treatment for people in all countries (Table 7 (REC6.2)), as well as accelerating efforts to distribute vaccines in low- and middle-income countries (Table 7 (REC6.10)).

Transfer agreements to increase production capacities in low- and middle-income countries should be expedited (Table 7 (REC6.6)). Pre-existing social and health inequities must be considered in pandemic preparedness and response going forward (Table 7 (REC6.7)). The findings call special attention to two vulnerable populations: children (Table 7 (REC6.5)) and those living within or fleeing from conflict zones (Table 7 (REC6.9)).

The pandemic has illustrated the risk of over-reliance on experts from a small number of disciplines (Table 3 (STMT6.8)), often excluding the expertise of community members (Table 4 (REC1.2)) and vulnerable groups (Table 3 (STMT6.7)). Instead, vulnerable groups should be sought out and actively engaged (Table 7 (REC6.3)). As noted in the communication domain, community leaders should also be engaged (Table 4 (REC1.1)). Multidisciplinary experts who understand local contexts should be included in developing national operational plans for ending COVID-19 as a public health threat (Table 7 (REC6.1)). COVID-19 tests and treatments should be affordable for all people in all countries (Table 7 (REC6.2)).

Discussion

Wide-ranging pandemic control measures^{59–62} have not ended COVID-19 as a public health threat^{63–68}. Although this study echoes some earlier findings—for example, the Independent Panel for Pandemic

Preparedness and Response³⁵, the European Union 2022 communication on preparedness and response⁶⁹ and WHO's 2022 plan on strategic preparedness⁵³—it is distinct from previous efforts²² given its design, which emphasized consensus building and the reporting of disagreement through the Delphi method, panellist diversity with regard to geography and disciplines, and the large sample size. The study's focus—ending COVID-19 as a public health threat—is defined as being evidenced by the resumption of pre-pandemic social, cultural, religious, political, healthcare, economic and educational activities in each country's context. Some retrospective matters (for example, pandemic root-cause analysis), theoretical questions and modelling were judged to be beyond the scope of the study.

Where possible, the study emphasizes recommendations that can be implemented in the short term (that is, in months, not years) to end COVID-19 as a public health threat. Although examples of countries implementing multiple recommendations exist (for example, free tests⁷⁰, combining widespread testing and free treatment of positive cases along with digital technologies⁷¹, the development of vaccines providing long-lasting protection against variants^{72,73}), the exceptions accentuate global challenges and provide new opportunities for action. Certain statements and recommendations resulting from this consensus process address gaps in WHO's strategic plan³¹, most strikingly, the failure to directly address the airborne nature of transmission. Initially, the WHO incorrectly labelled airborne transmission of SARS-CoV-2 as 'misinformation'. Only much later, after multidisciplinary scientific efforts, did the WHO recognize airborne transmission to be a predominant mode of transmission^{74–76}. By contrast, this panel recommends that 'risk communications clearly emphasize' (Table 6 (REC4.3)) the causal link between inhalation of SARS-CoV-2 and the transmission of COVID-19 as well as policy incentivizing 'structural prevention measures (for example, ventilation, air filtration) to mitigate airborne transmission' (Table 6 (REC4.1)).

The WHO's slow pace in directly addressing the airborne nature of transmission underscores why public health policy and risk communications should be based on evidence. For example, supposing that endemicity will result in lower virulence is an erroneous assumption^{77–79} that may exacerbate disproportionate risks of COVID-19 among vulnerable

Box 1

Cross-cutting themes for action to end COVID-19 as a public health threat

- (1) SARS-CoV-2 still moves among us—despite some governments moving on—requiring continued efforts and resources to save lives. Reservoirs exist from which variants of concern may yet emerge^{104,105}; possible endemicity⁴⁵ does not necessarily mean lower disease severity¹⁰⁶. Broad-based funding to develop long-lasting immunogenic vaccines must proceed concurrent with other prevention measures. The long-term impact of infection must be assessed, as long COVID has emerged as a chronic condition^{107–110}.
- (2) Vaccines are an effective tool against COVID-19 but will not alone end COVID-19 as a public health threat. Vaccination as a sole pandemic response strategy has limitations due to immune escape^{111–113}, waning immunity^{171,114,115}, inequitable access^{34,116}, vaccine hesitancy^{117–120} and the absence of immunization strategies¹²¹. A multifaceted public health vaccines-plus approach is needed, including testing, surveillance, treatment¹²², community engagement and implementation of social prevention measures (such as facemasks^{123,124}, distancing and quarantine), structural interventions (such as ventilation and air filtration)² and financial incentives (for example, support measures).
- (3) Multisectoral collaboration that centres on communities and fosters trust is needed. Ending COVID-19 as a public health threat requires whole-of-society and whole-of-government approaches engaging trusted community leaders and organizations, scientific experts, businesses, and other disciplines and sectors¹¹²⁵. This expanded pool of collaborators can best address diverse needs regarding modes of access, communication, innovation and trust among different populations^{126,127}.
- (4) Responsive health systems are crucial for responding to the COVID-19 pandemic and require coordinated government support. The persistent demand on health systems requires protecting the physical and mental wellbeing of healthcare workers; reducing economic barriers for equipment and treatment, including addressing supply-chain factors¹²⁸; strengthening primary care; and adopting a comprehensive, intersectoral, multilevel approach to preparedness and response activities.
- (5) Adverse forces challenge efforts to end the COVID-19 public health threat. Counteract sovereign state actors who are openly antagonistic toward science and public health and other entities with vested interests that disseminate false information. Public health authorities should build trust in evidence-based communications and partner with those monitoring and holding accountable disseminators of false information¹²⁹.
- (6) None of us is safe until everyone is safe. Pandemic inequities must end. This includes taking into account pre-existing social determinants of health, addressing access to affordable vaccines, tests, other supplies and treatment^{50,130}, and paying special attention to the needs of vulnerable groups (such as older^{131,132} and immunocompromised¹³³ individuals, children¹³⁴ and healthcare workers^{48,135,136}).

groups⁸⁰. By extension, engagement with communities through effective risk communication should remain a priority for all countries.

The WHO recognizes the infodemic as a key challenge to effective communication for general populations^{53,81–83}, vulnerable groups⁸⁴ and scientists⁸⁵. Governments, health authorities and healthcare providers should especially take care in the accuracy of their communications. The panel also emphasized that institutions should proactively monitor false health information and collaborate with trusted community leaders to refute it and enhance trust⁸⁶.

Given the disproportionate impact that the pandemic has had on vulnerable groups to date^{87–89}, the panel voiced concern that policy decisions must aim to find ways of lowering risk within these groups after resumption of the aforementioned activities (STMT6.1). As those vulnerable to COVID-19 in many countries can no longer rely on other individuals practising basic prevention measures (such as the use of face masks and isolating after testing positive), the structural changes recommended in this study (for example, indoor ventilation and filtration) assume heightened importance. Furthermore, COVID-19 continues to prompt global discussion and vigorous debate, particularly about tensions among medical ethics, civil liberties and pandemic control measures⁸⁰. This study is no exception, with statements STMT1.6 (blaming unvaccinated individuals) and STMT3.2 (individual decisions regarding vaccination) receiving the highest levels of disagreement, underscoring the need for equitable structural interventions. In countries with widespread availability of vaccines, it is important for health authorities to distinguish between those who have clearly refused and are unlikely ever to seek vaccination and those who remain hesitant and continue to delay vaccination⁹⁰. In the latter case, specific factors prolonging the delay can be addressed by targeted interventions. Finally, continued

uncertainty about the widespread consequences of long COVID and its implications for public health policy (REC2.9) is an ongoing concern^{91,92}.

Some innovations, notably vaccines^{37,38}, have not been equitably distributed to low- and middle-income countries, and others, such as high-quality facemasks, have not been widely adopted in high-income countries despite their availability⁹³. Some recommendations addressing pandemic inequities remain underleveraged; for example, providing more vaccines⁹⁴ to countries with a low percentage of people vaccinated (REC6.10). Other recommendations may necessitate increased funding and time—for example, calls for continued vaccine and treatment innovations (REC2.12, REC5.2, REC5.6).

Importantly, the single significant difference in levels of panel agreement between those working in high-income countries and those working in low- and middle-income countries pertained to the role of economic incentives (REC3.6), probably reflective of sociocultural distinctions or perhaps disagreement over feasibility in implementation and ethics concerns^{95,96}. Furthermore, 14% of the panellists considered themselves to be not qualified to respond to STMT4.3 concerning zoonotic variants, which probably indicates a lower understanding of biological vectors and the aetiology of variants among some of the disciplines included in the panel compared with the other topics covered⁹⁷.

As noted above, the panellists nearly unanimously agreed on and prioritized whole-of-society and whole-of-government approaches^{98–101} (Table 8). The panellists also prioritized recommendations for communicating effectively with the public and developing technologies (for example, vaccines, therapies and services) that can reach target populations (Table 8). Failure to use these approaches risks not only prolonging COVID-19 as a public health threat, but also further diversion of resources from efforts to achieve other extant public health goals^{102,103}.

Strengths and limitations

One of the strengths of this study is its use of Delphi methodology. By demonstrating increased agreement with each subsequent round, this method enabled us to determine whether our incorporation of feedback was successful in refining the statements and recommendations, increasing the degree of consensus and, in some cases, reaching unanimity. The consistently increasing mean levels of agreement with the consensus statements and recommendations observed across all three survey rounds strengthens our confidence in the relevance of the iterative Delphi process in eliciting feedback to improve subsequent rounds. This is particularly noteworthy given that the effort to incorporate feedback from the expert panel may have resulted in more complex (for example, multiple item) statements and recommendations. Generally, there may be concerns as to the clarity of such statements; however, levels of agreement tended to be either maintained or increased, providing greater confidence in their resonance with the panel. The overall high response rates across three survey rounds speaks to both the rigorous implementation of the method and the commitment of the assembled panel of experts. Endorsement of the resultant consensus statements and recommendations by 184 organizations in 72 countries (Supplementary Table 2) at the time of publication further testifies to their global relevance.

Although the Delphi method is a robust approach (Methods) to assess levels of agreement on specific issues and explore whether a consensus can be reached, it is not without limitations. A main concern pertains to the construction of a truly representative expert panel. The sequential, multimethod sampling approach that we used (see the 'Delphi expert panel member sample' section in the Methods) minimized potential bias from purposive sampling of a small group and, instead, generated a large, geographically and disciplinarily diverse panel from multiple sources (that is, the core group, nominees from the core group and corresponding authors of key COVID-19 literature). While potential panellists were identified from their work related to COVID-19, infectious diseases, public health preparedness and other fields, the chairs further confirmed their appropriateness for the study by instructing them to not participate if they felt they lacked expertise concerning the pandemic. This approach appears to have been appropriate, as only 5–14% of the panellists felt they were not qualified to respond to just 5 out of the 41 statements, and 3 of the 57 recommendations. Although conducting the study in English limited the participation to English speakers, the inclusion of experts from 112 countries and territories strengthens our confidence in the potential broad applicability of these recommendations to a range of cultures and countries. With regard to the mid-study convening of the core group to discuss issues raised in the initial survey rounds, another limitation may have been that we conducted it virtually rather than in person (see the 'Delphi data collection' section in the Methods).

Conclusions

The multidisciplinary panel's emphasis on actionable, near-term recommendations guided the Delphi consensus-building process and increased the relevance of the study's findings to a broad group of stakeholders, including governments, public health authorities, NGOs, community-based organizations, industry, and social media platforms and other media. This consensus study advances a global vision of informed decision-making on how the world can end COVID-19 as a public health threat without a return to sweeping limitations on civil liberties, without risking the health and lives of vulnerable groups, and without exacerbating economic burdens.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions

and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-022-05398-2>.

1. Leppo, K., Ollila, E., Peña, S., Wismar, M. & Cook, S. *Health in All Policies* (Ministry of Social Affairs and Health, Finland, 2013).
2. Greenhalgh, T., Griffiths, S., Gurdasani, D. & Hamdy, A. COVID-19: an urgent call for global 'vaccines-plus' action. *BMJ* **376**, o1 (2022).
3. Lazarus, J. et al. COVID-SCORE: a global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10). *PLoS ONE* **15**, e0240011 (2020).
4. Morens, D. M., Daszak, P., Markel, H. & Taubenberger, J. K. Pandemic COVID-19 joins history's pandemic legion. *mBio* **11**, 3 (2020).
5. *Pandemic Fatigue: Reinventing the Public to Prevent COVID-19: Policy Framework for Supporting Pandemic Prevention and Management: Revised Version November 2020* (WHO, 2020); <https://apps.who.int/iris/handle/10665/>
6. *COVID Live—Coronavirus Statistics* (Worldometer, 2022); <https://www.worldometers.info/coronavirus/#countries>.
7. Adam, D. The pandemic's true death toll: millions more than official counts. *Nature* **601**, 312–315 (2022).
8. Wang, H. et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. *Lancet* **399**, 1513–1536 (2022).
9. Kiss, P., Carcel, C., Hockham, C. & Peters, S. A. E. The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic review. *Eur. Hear. J. Qual. Care Clin. Outcomes* **7**, 18–27 (2021).
10. Alkatout, I. et al. Has COVID-19 affected cancer screening programs? A systematic review. *Front. Oncol.* **11**, 1540 (2021).
11. Murewanhema, G. & Makurumidze, R. Essential health services delivery in Zimbabwe during the COVID-19 pandemic: perspectives and recommendations. *Pan Afr. Med. J.* **35**, 143 (2020).
12. Shet, A. et al. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. *Lancet. Glob. Health* **10**, e186–e194 (2022).
13. Chen, Z. et al. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. *Nat. Genet.* **54**, 499–507 (2022).
14. Malick, M. S. S. & Fernandes, H. The genomic landscape of severe acute respiratory syndrome coronavirus 2. *Adv. Mol. Pathol.* **4**, 231–235 (2021).
15. Karthikeyan, S. et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. *Nature* **609**, 101–108 (2022).
16. *Coronavirus (COVID-19) Vaccinations. Statistics and Research* <https://ourworldindata.org/covid-vaccinations> (Our World in Data, 2021).
17. Pérez-Alós, L. et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. *Nat. Commun.* **13**, 1614 (2022).
18. Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* **399**, 924–944 (2022).
19. Lopez-Leon, S. et al. Long COVID in children and adolescents: a systematic review and meta-analyses. *Sci. Rep.* **12**, 9950 (2022).
20. Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci. Rep.* **11**, 16144 (2021).
21. Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat. Med.* **28**, 1706–1714 (2022).
22. Sachs, J. D. et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. *Lancet* **400**, 1224–1280 (2022).
23. *Global Trustworthiness Monitor* https://www.ipsos.com/sites/default/files/ct/news/documents/2022-01/global-trustworthiness-monitor-2021-report_0.pdf (Ipsos, 2022).
24. Gentilini, U. et al. *Social Protection and Jobs Responses to COVID-19: A Real-Time Review of Country Measures* (World Bank, 2020).
25. Haleem, A., Javaid, M. & Vaishya, R. Effects of COVID-19 pandemic in daily life. *Curr. Med. Res. Pract.* **10**, 78–79 (2020).
26. Ollivier-Barton, M. et al. SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties. *Lancet* **397**, 2234–2236 (2021).
27. Phillips, R. et al. Perceived threat of COVID-19, attitudes towards vaccination, and vaccine hesitancy: a prospective longitudinal study in the UK. *Br. J. Health Psychol.* **27**, 1354–1381 (2022).
28. Servick, K. Is it time to live with COVID-19? Some scientists warn of 'endemic delusion'. *Science* **375**, 703–704 (2022).
29. Mukaigawara, M. et al. An equitable roadmap for ending the COVID-19 pandemic. *Nat. Med.* **28**, 893–896 (2022).
30. Schneider, K. R., Fanzo, J. C., Haddad, L. & Rosero Moncayo, J. A new strategy for health and sustainable development in the light of the COVID-19 pandemic. *Lancet* **398**, 1029–1031 (2021).
31. Bar-Yam, Y. et al. The World Health Network: a global citizens' initiative. *Lancet* **398**, 1567–1568 (2021).
32. van der Linden, S., Roozenbeek, J. & Compton, J. Inoculating against fake news about COVID-19. *Front. Psychol.* **11**, 2928 (2020).
33. Larson, H. J., Gakidou, E. & Murray, C. J. L. The vaccine-hesitant moment. *N. Engl. J. Med.* **387**, 58–65 (2022).
34. Lazarus, J. V. et al. COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. *BMJ Glob. Health* **7**, e009010 (2022).
35. *COVID-19: Make it the Last Pandemic by The Independent Panel for Pandemic Preparedness & Response* <https://theindependentpanel.org/mainreport/> (The Independent Panel, 2021).
36. Batista, C. et al. The silent and dangerous inequity around access to COVID-19 testing: a call to action. *EClinicalMedicine* **43**, 101230 (2022).
37. Bayati, M., Noroozi, R., Ghanbari-Jahromi, M. & Jalali, F. S. Inequality in the distribution of Covid-19 vaccine: a systematic review. *Int. J. Equity Health* **21**, 122 (2022).

38. Lazarus, J. V. et al. Vaccinate fast but leave no one behind: a call to action for COVID-19 vaccination in Spain. *Commun. Med.* **1**, 12 (2021).
39. Pidiyar, V. et al. COVID-19 management landscape: a need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. *Vaccine* **40**, 5302–5312 (2022).
40. Public trust in scientists rose during the Covid-19 pandemic. *Wellcome Global Monitor* <https://wellcome.org/news/public-trust-scientists-rose-during-covid-19-pandemic-0> (Wellcome, 2021).
41. Shanka, M. S. & Menebo, M. M. When and how trust in government leads to compliance towards COVID-19 precautionary measures. *J. Bus. Res.* **139**, 1275–1283 (2021).
42. Skjefte, M. et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. *Eur. J. Epidemiol.* **36**, 197–211 (2021).
43. Lazarus, J. V. et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat. Med.* **27**, 225–228 (2021).
44. Petherick, A. et al. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue. *Nat. Hum. Behav.* **5**, 1145–1160 (2021).
45. *Third Round of the Global Pulse Survey on Continuity of Essential Health Services During the COVID-19 Pandemic* https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2022.1 (WHO, 2022).
46. Gross, J. V., Mohren, J. & Erren, T. C. COVID-19 and healthcare workers: a rapid systematic review into risks and preventive measures. *BMJ Open* **11**, e20210270 (2021).
47. Dzinamarira, T. et al. Risk factors for COVID-19 infection among healthcare workers. A first report from a living systematic review and meta-analysis. *Saf. Health Work* **13**, 263–268 (2022).
48. Denning, M. et al. Determinants of burnout and other aspects of psychological well-being in healthcare workers during the COVID-19 pandemic: a multinational cross-sectional study. *PLoS ONE* **16**, e0238666 (2021).
49. Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect. Dis.* **22**, 1293–1302 (2022).
50. Farina, M. & Lavazza, A. Advocating for greater inclusion of marginalized and forgotten populations in COVID-19 vaccine rollouts. *Int. J. Publ. Health* **66**, 1604036 (2021).
51. Mawani, F. N. et al. COVID-19 economic response and recovery: a rapid scoping review. *Int. J. Health Serv.* **51**, 247–260 (2021).
52. Nguyen, A., Guttentag, A., Li, D. & Meijgaard, J. V. The impact of job and insurance loss on prescription drug use: a panel data approach to quantifying the health consequences of unemployment during the COVID-19 pandemic. *Int. J. Health Serv.* **52**, 312–322 (2022).
53. *Strategic Preparedness, Readiness and Response Plan to end the Global COVID-19 Emergency in 2022* <https://www.who.int/publications/i/item/WHO-WHE-SPP-2022.1> (WHO, 2022).
54. Edwards, A. M., Baric, R. S., Saphire, E. O. & Ulmer, J. B. Stopping pandemics before they start: lessons learned from SARS-CoV-2. *Science* **375**, 1133–1139 (2022).
55. Haldane, V. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. *Nat. Med.* **27**, 964–980 (2021).
56. Pramesh, C. S. et al. Choosing wisely for COVID-19: ten evidence-based recommendations for patients and physicians. *Nat. Med.* **27**, 1324–1327 (2021).
57. Linas, B. P. et al. Projecting COVID-19 mortality as states relax nonpharmacologic interventions. *JAMA Health Forum* **3**, e220760 (2022).
58. Tam, K. M., Walker, N. & Moreno, J. Influence of state reopening policies in COVID-19 mortality. *Sci. Rep.* **12**, 1677 (2022).
59. Greer, S. L., King, E. J., da Fonseca, E. M. & Peralta-Santos, A. The comparative politics of COVID-19: the need to understand government responses. *Glob. Publ. Health* **15**, 1413–1416 (2020).
60. Bollyky, T. J. et al. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. *Lancet* **399**, 1489–1512 (2022).
61. Tang, J. W. et al. An exploration of the political, social, economic and cultural factors affecting how different global regions initially reacted to the COVID-19 pandemic. *Interface Focus* **12**, 20210079 (2022).
62. Zheng, C. et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. *Int. J. Infect. Dis.* **114**, 252–260 (2022).
63. Burn, E. et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. *Lancet Infect. Dis.* **22**, 1142–1152 (2022).
64. *Health at a Glance* <https://www.oecd-ilibrary.org/sites/ae3016b9-en/index.html?itemId=/content/publication/ae3016b9-en> (OECD, 2021).
65. Islam, N. et al. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. *BMJ* **373**, n1137 (2021).
66. Clarke, J. M., Majeed, A. & Beaney, T. Measuring the impact of COVID-19. *BMJ* **375**, e066952 (2021).
67. Strasser, Z., Hadavand, A., Shawn, M. & Estiri, H. SARS-CoV-2 Omicron variant is as deadly as previous waves after adjusting for vaccinations, demographics, and comorbidities. Preprint at *Research Square* <https://doi.org/10.21203/rs.3.rs-1601788/v1> (2022).
68. Mefsin, Y. M. et al. Epidemiology of infections with SARS-CoV-2 Omicron BA.2 variant, Hong Kong, January–March 2022. *Emerg. Infect. Dis.* **28**, 1856–1858 (2022).
69. Directorate-General for Health and Food Safety. *COVID-19—Sustaining EU Preparedness and Response: Looking Ahead* https://health.ec.europa.eu/publications/covid-19-sustaining-eu-preparedness-and-response-looking-ahead-0_en (European Commission, 2022).
70. Rader, B. et al. Use of at-home COVID-19 tests—United States, August 23, 2021–March 12, 2022. *MMWR* **71**, 489–494 (2022).
71. Lee, D., Heo, K. & Seo, Y. COVID-19 in South Korea: lessons for developing countries. *World Dev.* **135**, 105057 (2020).
72. Wang, C. Y. et al. A multipeptide SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. *J. Clin. Invest.* **132**, e157707 (2022).
73. Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. *Cell* **185**, 896–915 (2022).
74. WHO. *Fact Check: COVID-19 is Not Airborne* https://twitter.com/WHO/status/1243972193169616898?ref_src=twsrc%5Etfw (Twitter, 2020).
75. Lewis, D. Why the WHO took two years to say COVID is airborne. *Nature* **604**, 26–31 (2022).
76. Telenti, A. et al. After the pandemic: perspectives on the future trajectory of COVID-19. *Nature* **596**, 495–504 (2021).
77. Greenhalgh, T., Ozbilgin, M. & Tomlinson, D. How COVID-19 spreads: narratives, counter narratives, and social dramas. *BMJ* **378**, e069940 (2022).
78. Antia, R. & Halloran, M. E. Transition to endemicity: Understanding COVID-19. *Immunity* **54**, 2172–2176 (2021).
79. Whitaker, M. et al. Variant-specific symptoms of COVID-19 among 1,542,510 people in England. Preprint at *medRxiv* <https://doi.org/10.1101/2022.05.21.22275368> (2022).
80. Gostin, L. O., Friedman, E. A. & Wetter, S. A. Responding to COVID-19: how to navigate a public health emergency legally and ethically. *Hastings Cent. Rep.* **50**, 8–12 (2020).
81. Wang, Y., McKee, M., Torbica, A. & Stuckler, D. Systematic literature review on the spread of health-related misinformation on social media. *Soc. Sci. Med.* **240**, 112552 (2019).
82. Islam, M. S. et al. COVID-19-related infodemic and its impact on public health: a global social media analysis. *Am. J. Trop. Med. Hyg.* **103**, 1621–1629 (2020).
83. Purnat, T. Delivering actionable infodemic insights and recommendations for the COVID-19 pandemic response. *WER* **27**, 313–324 (2021).
84. Choukou, M. A. et al. COVID-19 infodemic and digital health literacy in vulnerable populations: a scoping review. *Digit. Health* **8**, 20552076221076927 (2022).
85. Palayew, A. et al. Pandemic publishing poses a new COVID-19 challenge. *Nat. Hum. Behav.* **4**, 666–669 (2020).
86. *Vaccination and Trust: How Concerns Arise and the Role of Communication in Mitigating Crises* (WHO, 2017).
87. Shadmi, E. et al. Health equity and COVID-19: global perspectives. *Int. J. Equity Health* **19**, 104 (2020).
88. Lebrasseur, A. et al. Impact of COVID-19 on people with physical disabilities: a rapid review. *Disabil. Health J.* **14**, 101014 (2021).
89. Kumar, N. et al. Sexual health (excluding reproductive health, intimate partner violence and gender-based violence) and COVID-19: a scoping review. *Sex. Transm. Infect.* **97**, 402–410 (2021).
90. Lazarus, J. V. et al. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. *Nat. Commun.* **13**, 3801 (2022).
91. Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat. Med.* **28**, 1461–1467 (2022).
92. *A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021* https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (WHO, 2021).
93. Li, H. et al. Efficacy and practice of facemask use in general population: a systematic review and meta-analysis. *Transl. Psychiatry* **2022**, 49 (2022).
94. Yamey, G. et al. It is not too late to achieve global covid-19 vaccine equity. *BMJ* **376**, e070650 (2022).
95. Jarrett, C. et al. Strategies for addressing vaccine hesitancy—a systematic review. *Vaccine* **33**, 4180–4190 (2015).
96. Persad, G. & Emanuel, E. J. Ethical considerations of offering benefits to COVID-19 vaccine recipients. *JAMA* **326**, 221–222 (2021).
97. Vora, N. M. et al. Want to prevent pandemics? Stop spillovers. *Nature* **605**, 419–422 (2022).
98. Chiriboga, D., Garay, J., Buss, P., Madrigal, R. S. & Rispel, L. C. Health inequity during the COVID-19 pandemic: a cry for ethical global leadership. *Lancet* **395**, 1690–1691 (2020).
99. Wenham, C. What went wrong in the global governance of COVID-19? *Brit. Med. J.* **372**, n303 (2021).
100. Global Preparedness Monitoring Board. *From Worlds Apart to a World Prepared* (WHO, 2021).
101. Sirleaf, R., Johnson, H. E. E. & Clark, H. H. *Transforming or Tinkering? Inaction Lays the Groundwork for Another Pandemic* (The Independent Panel for Pandemic Preparedness and Response, 2022).
102. Shulla, K. et al. Effects of COVID-19 on the Sustainable Development Goals (SDGs). *Discov. Sustain.* **2**, 15 (2021).
103. *The Sustainable Development Goals Report 2021* <https://unstats.un.org/sdgs/report/2021/> (UN, 2021).
104. *Tracking SARS-CoV-2 variants* <https://www.who.int/activities/tracking-SARS-CoV-2-variants> (WHO, 2022).
105. Chandler, J. C. et al. SARS-CoV-2 exposure in wild white-tailed deer (*Odocoileus virginianus*). *Proc. Natl Acad. Sci. USA* **118**, e2114828118 (2021).
106. Nesteruk, I. Influence of possible natural and artificial collective immunity on new COVID-19 pandemic waves in Ukraine and Israel. *Explor. Res. Hypothesis Med.* **7**, 8–18 (2022).
107. Taquet, M. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS Med.* **18**, e1003773 (2021).
108. Carson, G. et al. Research priorities for long COVID: refined through an international multi-stakeholder forum. *BMC Med.* **19**, 84 (2021).
109. Buonsenso, D. et al. Preliminary evidence on long COVID in children. *Acta Paediatr.* **110**, 2208–2211 (2021).
110. Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long COVID—mechanisms, risk factors, and management. *BMJ* **374**, n1648 (2021).
111. Khan, K. et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. *Nat. Commun.* **13**, 4686 (2022).
112. Noh, J. Y., Jeong, H. W. & Shin, E. C. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. *Signal Transduct. Target. Ther.* **6**, 203 (2021).
113. Tian, D., Sun, Y. H., Zhou, J. M. & Ye, Q. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. *J. Med. Virol.* **94**, 847–857 (2022).

114. Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. *N. Engl. J. Med.* **385**, e85 (2021).
115. Ssentongo, P. et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. *BMC Infect. Dis.* **22**, 439 (2022).
116. *Global Dashboard for Vaccine Equity* <https://data.undp.org/vaccine-equity/> (UNDP Data Futures Platform, 2022).
117. MacDonald, N. E. et al. Vaccine hesitancy: definition, scope and determinants. *Vaccine* **33**, 4161–4164 (2015).
118. El-Mohandes, A. et al. COVID-19 vaccine acceptance among adults in four major US metropolitan areas and nationwide. *Sci. Rep.* **11**, 21844 (2021).
119. Duan, Y. et al. Disparities in COVID-19 vaccination among low-, middle-, and high-income countries: the mediating role of vaccination policy. *Vaccines* **9**, 905 (2021).
120. Sabahelzain, M. M., Hartigan-Go, K. & Larson, H. J. The politics of COVID-19 vaccine confidence. *Curr. Opin. Immunol.* **71**, 92–96 (2021).
121. Meng, H., Mao, J. & Ye, Q. Booster vaccination strategy: necessity, immunization objectives, immunization strategy, and safety. *J. Med. Virol.* **94**, 2369–2375 (2022).
122. Brandon, Ng.T. S., Leblanc, K., Yeung, D. F. & Tsang, T. S. M. Medication use during COVID-19: review of recent evidence. *Can. Fam. Physician* **67**, 171–179 (2021).
123. Chou, R., Dana, T. & Jungbauer, R. Update alert 8: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. *Ann. Intern. Med.* **175**, W108–W109 (2022).
124. Kuhfeldt, K. et al. Examination of SARS-CoV-2 in-class transmission at a large urban university with public health mandates using epidemiological and genomic methodology. *JAMA Netw. Open* **5**, e2225430 (2022).
125. Samaan, G. et al. The World Health Organization's actions within the United Nations system to facilitate a whole-of-society response to COVID-19 at country level. *Front. Publ. Health* **9**, 831220 (2022).
126. Bump, J. B., Friberg, P. & Harper, D. R. International collaboration and COVID-19: what are we doing and where are we going? *BMJ* **372**, n180 (2021).
127. Tanveer, S., Rowhani-Farid, A., Hong, K., Jefferson, T. & Doshi, P. Transparency of COVID-19 vaccine trials: decisions without data. *BMJ Evid. Based Med.* **27**, 199–205 (2021).
128. Moosavi, J., Fathollahi-Fard, A. M. & Dulebenets, M. A. Supply chain disruption during the COVID-19 pandemic: recognizing potential disruption management strategies. *Int. J. Disaster Risk Reduct.* **75**, 102983 (2022).
129. Purnat, T. D., Wilson, H., Nguyen, T. & Briand, S. EARS—a WHO platform for AI-supported real-time online social listening of COVID-19 conversations. *Stud. Health Technol. Inform.* **281**, 1009–1010 (2021).
130. Wu, E.-L. et al. Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study. *J. Gen. Intern. Med.* **37**, 2505–2513 (2022).
131. Mølhav, M., Agergaard, J. & Wejse, C. Clinical management of COVID-19 patients—an update. *Semin. Nucl. Med.* **52**, 4–10 (2022).
132. *No-One is Safe Until Everyone is Safe—Why We Need a Global Response to COVID-19* <https://www.unhcr.org/news/press/2021/5/60a7fc9b4/statement-no-one-safe-safe-need-global-response-covid-19.html> (UNHCR, 2021).
133. Marra, A. R. et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. *J. Infect.* **84**, 297–310 (2022).
134. Orben, A., Tomova, L. & Blakemore, S. J. The effects of social deprivation on adolescent development and mental health. *Lancet Child Adolesc. Health* **4**, 634–640 (2020).
135. Paris, C. et al. Risk factors for SARS-CoV-2 infection among health care workers. *Am. J. Infect. Control* **50**, 375–382 (2022).
136. Cahill, A. G. et al. Occupational risk factors and mental health among frontline health care workers in a large US metropolitan area during the COVID-19 pandemic. *Prim. Care Companion CNS Disord.* **24**, 40038 (2022).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

¹Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. ²Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. ³City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York City, NY, USA. ⁴Independent Researcher, Sioux Falls, SD, USA. ⁵University of KwaZulu-Natal, Durban, South Africa. ⁶Centre for the AIDS Program of Research in South Africa (CAPRISA), Durban, South Africa. ⁷Weill Cornell Medicine, Cornell University, Ithaca, NY, USA. ⁸Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar. ⁹Pan American Health Organisation, Washington, DC, USA. ¹⁰UNITE Global Parliamentarians Network, Lisbon, Portugal. ¹¹Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. ¹²Institute of Health Sciences (CIIS), Catholic University of Portugal, Lisbon, Portugal. ¹³University of Colorado School of Medicine, Aurora, CO, USA. ¹⁴Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil. ¹⁵University of Bahia, Salvador, Brazil. ¹⁶New England Complex Systems Institute, Cambridge, MA, USA. ¹⁷Manhiça Health Research Center (CISM), Maputo, Mozambique. ¹⁸Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain. ¹⁹Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain. ²⁰Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), Madrid, Spain. ²¹Doctors Without Borders (MSF), Geneva, Switzerland. ²²Baraka Impact Finance, Geneva, Switzerland. ²³Payne Institute, Colorado School of Mines, Golden, CO, USA. ²⁴National Yang Ming Chiao Tung University, Taipei, Taiwan. ²⁵Emory School of Medicine, Atlanta, GA, USA. ²⁶University of New South Wales (UNSW) Sydney, Sydney, New South Wales, Australia. ²⁷Chinese Center for Disease Control and Prevention, Beijing, China. ²⁸The O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC, USA. ²⁹Burnet Institute, Melbourne, Victoria, Australia. ³⁰Department of Chemistry, University of Colorado Boulder, Boulder, CO, USA. ³¹Cooperative Institute for Research in Environmental Sciences (CIRES), University of Colorado Boulder, Boulder, CO, USA. ³²Christian Medical College (CMC), Vellore, India. ³³Wilton Park, Steyning, UK. ³⁴Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, Slovenia. ³⁵Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. ³⁶The London School of Hygiene & Tropical Medicine, London, UK. ³⁷University Teaching Hospital of Butare, Butare, Rwanda. ³⁸Paris Dauphine University - PSL, Paris, France. ³⁹French National Centre for Scientific Research (CNRS), Grenoble, France. ⁴⁰University College London (UCL), London, UK. ⁴¹Dr. Rajendra Prasad Government Medical College, Himachal Pradesh, India. ⁴²James P. Grant School of Public Health, BRAC University, Dhaka, Bangladesh. ⁴³Plenitud Foundation, Santo Domingo, Dominican Republic. ⁴⁴University of Costa Rica, San José, Costa Rica. ⁴⁵Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. ⁴⁶Independent Philosopher, Copenhagen, Denmark. ⁴⁷Department of Neurosurgery, Houston Methodist Research Institute, Houston, TX, USA. ⁴⁸International Digital Health & AI Research Collaborative (I-DAIR), Geneva, Switzerland. ⁴⁹University of Global Health Equity, Kigali, Rwanda. ⁵⁰University of Malaya, Kuala Lumpur, Malaysia. ^{*}A list of authors and their affiliations appears online. [✉]e-mail: Jeffrey.Lazarus@isglobal.org

Article

The COVID-19 Consensus Statement Panel

Jeffrey V. Lazarus^{1,2,3}, Diana Romero³, Christopher J. Kopka⁴, Salim Abdool Karim^{5,6}, Laith J. Abu-Raddad^{7,8}, Gisele Almeida⁹, Ricardo Baptista-Leite^{10,11,12}, Joshua A. Barocas¹³, Mauricio Barreto^{14,15}, Yaneer Bar-Yam¹⁶, Riquie Bassat^{17,18,19,20}, Carolina Batista^{21,22}, Morgan Bazilian²³, Shu-Ti Chiot²⁴, Carlos del Rio²⁵, Gregory J. Dore²⁶, George F. Gao²⁷, Lawrence O. Gostin²⁸, Margaret Hellard²⁹, Jose L. Jimenez^{30,31}, Gagandeep Kang³², Nancy Lee³³, Mojca Matičič^{34,35}, Martin McKee³⁶, Sabin Nsanzinana³⁷, Miquel Oliu-Barton³⁸, Barry Pradelski³⁹, Oksana Pyzik⁴⁰, Kenneth Rabin³, Sunil Raina⁴¹, Sabina Faiz Rashid⁴², Magdalena Rathe⁴³, Rocio Saenz⁴⁴, Sudhvir Singh⁴⁵, Malene Trock-Hempler⁴⁶, Sonia Villapol⁴⁷, Peiling Yap⁴⁸, Agnes Binagwaho⁴⁹, Adeeba Kamarulzaman⁵⁰, Ayman El-Mohandes³, Salim Abdulla⁵¹, Sarah Addeleman⁵², Gulnara Aghayeva⁵³, Raymond Agius⁵⁴, Mohammed Ahmed⁵⁵, Mohamed Ahmed Ramy⁵⁶, Pedro Aide¹⁷, Soo Alemam⁵⁷, Jean-Patrick Alfred⁵⁸, Shamim Ali⁵⁹, Jorge Aliaga⁶⁰, Tammam Aloudat⁶¹, Saleh A. Alqahtani⁶², Jameela Al-Salman⁶³, John H. Amuasi⁶⁴, Anurag Agrawal⁶⁵, Wagida Anwar⁶⁶, Tania Araujo-Jorge¹⁴, Osvaldo Artaza⁶⁷, Leyla Asadi⁶⁸, Yaw Awuku⁶⁹, Michael Baker⁷⁰, Lorena Barberia⁷¹, Ernesto Bascolo⁶⁹, Paul Belcher⁷², Lizett Bell⁷³, Adele Benzaken⁷⁴, Emil Bergholtz⁷⁵, Nahid Bhadelia⁷⁶, Anant Bhan⁷⁷, Stephane Bilodeau⁷⁸, Ricardo Bitrán⁷⁹, Philomena Bluyssen⁸⁰, Arnold Bosman⁸¹, Fernando A. Bozza¹⁴, Melanie M. Brinkmann⁸², Andrew Brown⁸³, Bruce Mellado⁸⁴, Elizabeth Bukus⁸⁵, Chris Bullen⁸⁶, Giorgio Buonanno⁸⁶, Rochelle Burgess⁴⁰, Matthew Butler⁸⁷, Pauline Byakika-Kibwika⁸⁸, Baltica Cabieses⁸⁹, Gunilla Carlsson⁹⁰, Fidella Cascini⁹¹, Chishala Chabala⁹², Mohamed Chakroun⁹³, K. K. Cheng⁹⁴, Agnes Chetty⁹⁵, Dmytro Chumachenko⁹⁶, Gregg Consalves⁹⁷, Andrew Conway Morris⁹⁸, Ahmed Cordie⁹⁹, Tumanj Corrah¹⁰⁰, Brenda Crabtree-Ramirez¹⁰¹, Naranjargal Dashdorj¹⁰², Nadav Davidovitch¹⁰³, Luis Eugenio de Souza¹⁵, Akshay Chand Dharwal¹⁰⁴, Elena Draicã¹⁰⁵, Onder Ergonul¹⁰⁶, Ngozi A. Erondut¹⁰⁶, Mohammad Yasir Essar¹⁰⁷, Andrew Ewing¹⁰⁸, Gonzalo Fanjul¹, Daniel Feierstein¹⁰⁹, Eric Feigl-Ding¹¹⁰, Ramon Figueroa¹¹¹, John Peter Figueroa¹¹², Dale Fisher¹¹³, Walter Flores¹¹⁴, David A. Forero-Peña¹¹⁵, Howard Frumkin¹¹⁶, Amiran Garmkrelidze¹¹⁷, Monica Gandhi¹¹⁸, Patricia Garcia¹¹⁹, Alberto L. Garcia-Basteno¹, Adolfo Garcia-Sastre¹²⁰, Suneeta Garg¹²¹, F. A. Gbeasor-Komlanvi¹²², Carlos Gershenson¹²³, Ishwar Gilada¹²⁴, Ligia Giovannella¹⁴, Marino González¹²⁵, Manfred S. Green¹²⁶, Trisha Greenhalgh¹²⁷, Paul Griffin¹²⁸, Stephen Griffin¹²⁹, Beatriz Grinsztejn¹³⁰, Tanu Anand¹³¹, Germán Guerra¹³², Renzo Guinto³³, Mariusz Gujski¹³⁴, Rahmet Guner¹³⁵, Adam Hamdy¹³⁶, Marian-Gabriel Hăncean¹⁰⁵, Abusayed Haniffa¹³⁷, Kenneth Y. Hartigan-Gore¹³⁸, Hoda K. Hassan¹³⁹, Simon I. Hay¹¹⁶, Matti T. J. Heino¹⁴⁰, Zdenek Hel¹⁴¹, Peter Hotez¹⁴², Jia Hu¹⁴³, Mirsada Hukić¹⁴⁴, Carel IJsselmuide¹⁴⁵, Davidsen Iroko⁶⁹, Maged Iskarous¹⁴⁶, Chimaraoke Izugbara¹⁴⁷, Choolwe Jacobs⁸², Alejandro R. Jadad¹⁴⁸, Fyezah Jehan¹⁴⁹, Ayana Jordan¹⁵⁰, Imane Jroundi¹⁵¹, Kevin Kain¹⁵², Fatjona Kamberi¹⁵³, Eduard Karamov¹⁵⁴, Abraar Jordan¹⁵⁵, Rebecca Katz²⁹, Aris Katzourakis¹²⁷, Abigail Kazembe¹⁵⁶, Faryal Khamis¹⁵⁷, Komiljon Khamzayev¹⁵⁸, Judy Khanyola⁴⁹, Kamlesh Khunti¹⁵⁹, Elsie Kiguli-Matwadda¹⁶⁰, Woo Jo Kim⁶¹, Bruce J. Kirenga⁸⁸, Daniel Klimovskiy¹⁶², Brittany L. Kmush⁶³, Felicia Knaut¹⁶⁴, Manolis Kogevasinas¹, Frederik Kristensen¹⁶⁶, Dinesh Kumar⁴¹, Raman Kumar¹⁶⁶, Amanda Kvalsvig⁷⁰, Marcus V. Lacerda¹⁴, Arush Lal¹⁶⁷, Tom Lawton¹⁶⁸, Jay Lemery¹³, Anthony J. Leonard¹⁶⁹, Yugo Li¹⁷⁰, Jan Lötvall¹⁰⁸, Mohamed Lounis¹⁷¹, Deza Maceira¹⁷², C. Raina MacIntyre⁶⁶, Azzeddine Madani¹⁷³, Gkikas Magiorkinis¹⁷⁴, Reial Malekzadeh¹⁷⁵, Marc Choisy¹⁷⁶, Jasmine R. Marcelin¹⁷⁷, Guy B. Marks²⁶, Linsey Marr¹⁷⁸, Jeanne Marrazzo¹⁴¹, Antonieta Martina¹⁷⁹, José M. Martín-Moreno¹⁸⁰, Carlos Mateos¹⁸¹, Mayfong Maxmay¹⁸², Jean Baptiste Mazarati¹⁸³, Souleymane Mboup⁸⁴, Jennifer McDonald⁵², Faye McMillan²⁶, Enkeleint Mechlili¹⁸³, Andre Medici¹⁸⁵, Sarah L. M. Davis⁶¹, Petra Meier¹⁸⁶, Ziad A. Memish¹⁸⁷, Jaiideep Menon¹⁸⁸, Purnima Menon¹⁸⁹, Jonathan Mesiano-Crookston¹⁹⁰, Susan Michie⁴⁰, Ivana Mikolasevic¹⁹¹, Ognjen Milicevic¹⁹², Asit Kumar Mishra¹⁹³, Rahma Mohamed⁹⁹, Ali H. Mokdad¹¹⁶, Michele Monroy-Valle¹⁹⁴, Lidia Morawska¹⁹⁵, Sterghios A. Moschos¹⁹⁶, Karam Motawea¹⁹⁷, Sayed Hamid Mousavi¹⁹⁸, Ghina Mumtaz¹⁹⁹, Peter K. Munene²⁰⁰, Carmen Muñoz Almagro²⁰¹, Janet Muriuki²⁰², Sylvia Musingo²⁰³, Denise Nanche¹, C. David Naylor¹⁸², Nicaise Ndembu²⁰⁴, Juraj Nemecek²⁰⁵, Igor Nesteruk²⁰⁶, Christine Ngaruiya²⁰⁷, Hung Nguyen²⁰⁸, Dafina Nikolova²⁰⁹, Dorit Nitzan¹⁰³, Ole Norheim²¹⁰, Mohammed Noushad²¹¹, Francine Ntoumi^{212,213}, Gunhild Alvik Nyborg^{165,214}, Eleanor Ochodo⁶⁵, Zekaver Odabas²¹⁵, Mbah Patrick Okwen²¹⁶, Keiser Olivia²¹⁷, David S. Y. Ong²¹⁸, Ijeoma Opara²¹⁹, Miguel Orozco²²⁰, Hitoshi Oshitani¹²¹, Christina Paget¹⁴⁰, Madhukar Pai²²², Björg Pálsdóttir²²³, Georgios Papatheodoridis¹⁷⁴, Dimitrios Paraskevas¹⁷⁴, Jeanna Parsons Leigh²²⁴, Bernard Pécoul²²⁵, Andreas Peichl²²⁶, Eddy Perez-Then²²⁷, Phuc Ham Duc²²⁸, Cécile Philippe²²⁹, Andrea Pineda Rojas²³⁰, Courtney Pladsen²³¹, Anton Pozniak²³², Rodrigo Quiroga²³³, Huma Qureshi²³⁴, Sanjay Rampal¹⁶⁰, Megan Ranney²³⁵, Laura Rathe⁴³, Scott Ratzan³, Henriette Raventos⁴⁴, Helen Rees⁸⁴, Renata Reis²¹, Walter Ricciardi⁹¹, Nesrine Rizk¹⁹⁹, Magda Robalo²³⁶, Eleanor Robertson²³⁷, Leanne Robinson²⁹, Casper Rokx²³⁸, Tamsin Ros²³⁹, John-Arne Røttingen²⁴⁰, Meir Rubin²⁴¹, Kiat Ruxrungtorn²⁴², Shakhlo Sadirova²⁴³, Senjuti Saha²⁴⁴, Nelly Salgado²⁴⁵, Lizet Sanchez²⁴⁶, Thurka Sangaramoorthy²⁴⁷, Carolina Santamaria-Ulloa⁴⁴, Renata Santos²¹, Bisher Sawaf²⁴⁸, Matthias F. Schneider²⁴⁹, Robert T. Schooley²⁵⁰, Alper Sener²⁵¹, Jaime Sepulveda¹⁸, Jaffer Shah¹⁹⁸, Mosa Shibani²⁵², Sheikh Shoib²⁵³, Izukanji Sikazwe²⁵⁴, Aistis Šimaitis²⁵⁵, Amandeep Singh Gill⁴⁸, Natia Shkvtiridze¹¹⁷, Milka Sokolovic⁷², Roma Solomon²⁵⁶, Xavier Solórzano²⁵⁷, Sandra A. Springer²⁰⁷, Jakub Šrol²⁵⁸, Anthony Staines²⁵⁹, Henry T. Stelfox²⁶⁰, Steffanie Strathdee²⁶⁰, Lokman Hakim Sulaiman²⁶¹, Brett Sutton²⁶², Dag Svane²⁶³, Sarya Swed²⁶⁴, Vana Syspa¹⁷⁴, Kristine Sørensen²⁶⁵, Raji Tajudeen²⁶⁶, Amy Tan⁶⁷, Julian Tang¹⁵⁷, Marcel Tanne²⁶⁸, Tavpriteseth Sathi²⁶⁹, Marleen Temmerman²⁷⁰, Kyu Kyu Than²⁷¹, Halidou Tinto²⁷², Sènoué Pacôme Tométissi²⁷³, Irene Torres²⁷⁴, K. P. Tshering²⁷⁵, Sotirios Tsioufas¹⁷⁴, Benjamin Tsofa⁸⁵, Anders Vahle⁵⁷, Juan Rafael Vargas⁴⁴, Ivan Dario Velez Bernal²⁷⁶, Deisy Ventura⁷¹, Rafael Vilasanjuan¹, Joe Vipond²⁶⁰, Sarah Wamala-Andersson²⁷⁷, Pawel Wargocki²⁷⁸, Robert West⁴⁰, Angela Weyand²⁷⁹, Trenton M. White¹²⁸⁰, Guntram Wolff²⁸¹, Maosheng Yao²⁸², Christian A. Yates²⁸³, Georgina Yeboah²⁸⁴, Lee Yee-Sin²⁸⁵, Siyan Yi¹¹³, Yik-Ying Teo¹¹³, Poovorawan Yong²⁴², Victor Zamora-Mesia²⁸⁶ & Anne Øvrehus²⁸⁷

⁵⁵Mogadishu University, Mogadishu, Somalia. ⁵⁶Generations for Health, Madrid, Spain. ⁵⁷Karolinska University Hospital, Stockholm, Sweden. ⁵⁸Ministry of Health and Population, Port-au-Prince, Haiti. ⁵⁹Moi University, Eldoret, Kenya. ⁶⁰Hurlingham National University, Hurlingham, Argentina. ⁶¹Graduate Institute of International and Development Studies, Geneva, Switzerland. ⁶²King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. ⁶³Salmaniya Medical Complex, Manama, Bahrain. ⁶⁴Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. ⁶⁵Trivedi School of Biosciences, Ashoka University, Sonapat, India. ⁶⁶Community Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ⁶⁷Faculty of Health and Social Sciences, University of The Americas, Santiago, Chile. ⁶⁸University of Alberta, Edmonton, Alberta, Canada. ⁶⁹University of Health and Allied Sciences, Ho, Volta, Ghana. ⁷⁰University of Otago, Wellington, New Zealand. ⁷¹University of Sao Paulo, Sao Paulo, Brazil. ⁷²European Public Health Alliance, Brussels, Belgium. ⁷³Ministry of Health and Wellness Belize, Belmopan, Belize. ⁷⁴Aids Healthcare Foundation, São Paulo, Brazil. ⁷⁵Department of Physics, Stockholm University, Stockholm, Sweden. ⁷⁶Boston University Center for Emerging Infectious Diseases Policy and Research (CEID), Boston, MA, USA. ⁷⁷Centre For Ethics, Yenepeya University, Mangaluru, India. ⁷⁸Smart Phases, Plattsburgh, NY, USA. ⁷⁹Bitran y Asociados, Santiago, Chile. ⁸⁰Delft University of Technology, Delft, The Netherlands. ⁸¹Transmissible, Houten, The Netherlands. ⁸²Institute of Genetics, Technische Universität Braunschweig, Braunschweig, Germany. ⁸³Management Sciences for Health, Medford, MA, USA. ⁸⁴University of the Witwatersrand, Johannesburg, South Africa. ⁸⁵Kenya Medical Research Institute, Nairobi, Kenya. ⁸⁶University of Cassino and Southern Lazio, Cassino, Italy. ⁸⁷King's College London, London, UK. ⁸⁸Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. ⁸⁹Universidad del Desarrollo, Santiago, Chile. ⁹⁰The Global Fund, Geneva, Switzerland. ⁹¹Catholic University of the Sacred Heart, Rome, Italy. ⁹²University of Zambia, Lusaka, Zambia. ⁹³Fattouma Bourguiba Teaching Hospital, Monastir, Tunisia. ⁹⁴Institute of Applied Health Research, University of Birmingham, Birmingham, UK. ⁹⁵Ministry of Health Seychelles, Victoria, Seychelles. ⁹⁶National Aerospace University "Kharkiv Aviation Institute", Kharkiv, Ukraine. ⁹⁷Yale School of Public Health, New Haven, CT, USA. ⁹⁸University of Cambridge, Cambridge, UK. ⁹⁹Cairo University Hospitals, Cairo, Egypt. ¹⁰⁰Africa Research Excellence Fund (AREF), London, UK. ¹⁰¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ¹⁰²Onom Foundation, Ulaanbaatar, Mongolia. ¹⁰³Ben Gurion University of the Negev, Beer Sheva, Israel. ¹⁰⁴National Center for Disease Control and National Vector Borne Disease Control Programme, Government of India, Delhi, India. ¹⁰⁵University of Bucharest, Bucharest, Romania. ¹⁰⁶Koç University İsbank Center for Infectious Diseases, Istanbul, Turkey. ¹⁰⁷Kabul University of Medical Sciences, Kabul, Afghanistan. ¹⁰⁸University of Gothenburg, Gothenburg, Sweden. ¹⁰⁹CONICET/National University of Tres de Febrero, Caseros, Argentina. ¹¹⁰Federation of American Scientists, Washington, DC, USA. ¹¹¹Social Security Board, Belize City, Belize. ¹¹²The University of the West Indies, Kingston, Jamaica. ¹¹³National University of Singapore, Singapore, Singapore. ¹¹⁴Center for the Study of Equity and Governance in Health Systems, Guatemala City, Guatemala. ¹¹⁵Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela. ¹¹⁶Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA. ¹¹⁷National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia. ¹¹⁸UCSF, San Francisco, CA, USA. ¹¹⁹School of Public Health, Cayetano Heredia University, Lima, Peru. ¹²⁰Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ¹²¹MAMC & Associated Hospitals New Delhi, New Delhi, India. ¹²²University of Lomé, Lomé, Togo. ¹²³Universidad Nacional Autónoma de México, Mexico City, Mexico. ¹²⁴Organised Medicine Academic Guild—OMAG, Mumbai, India. ¹²⁵Simon Bolívar University, Caracas, Venezuela. ¹²⁶University of Haifa, Haifa, Israel. ¹²⁷University of Oxford, Oxford, UK. ¹²⁸University of Queensland, Brisbane, Queensland, Australia. ¹²⁹University of Leeds, Leeds, UK. ¹³⁰National Institute of Infectology Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil. ¹³¹Indian Council of Medical Research, New Delhi, India. ¹³²National Institute of Public Health, Cuernavaca, Mexico. ¹³³St Luke's Medical Center College of Medicine, Quezon City, The Philippines. ¹³⁴Department of Public Health, Medical University of Warsaw, Warsaw, Poland. ¹³⁵Ankara City Hospital Infectious Diseases and Clinical Microbiology, Ankara, Turkey. ¹³⁶Independent Researcher, Port Louis, Mauritius. ¹³⁷Ministry of Health, Colombo, Sri Lanka. ¹³⁸Ateneo School of Government, Quezon City, The Philippines. ¹³⁹Independent Consultant, Cairo, Egypt. ¹⁴⁰University of Helsinki, Helsinki, Finland. ¹⁴¹University of Alabama at Birmingham, Birmingham, AL, USA. ¹⁴²National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. ¹⁴³9 To Zero, Calgary, Alberta, Canada. ¹⁴⁴Center for Disease Control and Geohealth Studies, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. ¹⁴⁵COHRED, Geneva, Switzerland. ¹⁴⁶Independent Consultant, Cairo, Egypt. ¹⁴⁷International Center for Research on Women, Washington, DC, USA. ¹⁴⁸Centre for Digital Therapeutics, Toronto, Ontario, Canada. ¹⁴⁹Aga Khan University, Karachi, Pakistan. ¹⁵⁰NYU Grossman School of Medicine, New York City, NY, USA. ¹⁵¹School of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco. ¹⁵²University of Toronto, Toronto, Ontario, Canada. ¹⁵³Research Centre of Public Health, Faculty of Health, University of Vlore "Ismail Qemali" Albania, Vlorë, Albania. ¹⁵⁴Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. ¹⁵⁵Division of Infectious Disease & Geographic Medicine, Stanford University, Stanford, CA, USA. ¹⁵⁶Kamuzu University of Health Sciences, Blantyre, Malawi. ¹⁵⁷Royal Hospital, Ministry of Health, Muscat, Oman. ¹⁵⁸Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan. ¹⁵⁹University of Leicester, Leicester, UK. ¹⁶⁰African Center for Global Health and Social Transformation, Kampala, Uganda. ¹⁶¹Division of Infectious Diseases, Guro Hospital, College of Medicine Korea University, Seoul, Republic of Korea. ¹⁶²Comenius University in Bratislava, Bratislava, Slovakia. ¹⁶³Syracuse University, Syracuse, NY, USA. ¹⁶⁴University of Miami Institute for Advanced Study of the Americas, Coral Gables, FL, USA. ¹⁶⁵Coalition of Epidemic Preparedness Innovations (CEPI), Oslo, Norway. ¹⁶⁶Institute of Family Medicine and Primary Care, Greater Noida, India. ¹⁶⁷London School of Economics & Political Science, London, UK. ¹⁶⁸Bradford Institute for Health Research & Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK. ¹⁶⁹St Georges University of London, London, UK. ¹⁷⁰The University of Hong Kong, Hong Kong, China. ¹⁷¹University Ziane Achour Djelfa, Djelfa, Algeria. ¹⁷²University of Buenos Aires/Health Systems Global, Buenos Aires, Argentina. ¹⁷³Faculty of Social and Human Sciences, Khemis-Miliana University, Khemis-Miliana, Algeria. ¹⁷⁴National and Kapodistrian University of Athens, Athens, Greece. ¹⁷⁵Digestive Disease Research Institute Tehran University of Medical Sciences, Tehran, Iran. ¹⁷⁶Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

⁵¹Ifakara Health Institute, Dar es Salaam, Tanzania. ⁵²University of Ottawa, Ottawa, Ontario, Canada. ⁵³Baku Health Centre, Baku, Azerbaijan. ⁵⁴The University of Manchester, Manchester, UK.

¹⁷⁷University of Nebraska Medical Center, Omaha, NE, USA. ¹⁷⁸Virginia Tech, Blacksburg, VA, USA. ¹⁷⁹University of Cabo Verde, Praia, Cape Verde. ¹⁸⁰Department of Preventive Medicine and Public Health and INCLIVA, University of Valencia, Valencia, Spain. ¹⁸¹Instituto #SaludsinBulos, Madrid, Spain. ¹⁸²University of Health Sciences, Ministry of Health, Vientiane, Lao People's Democratic Republic. ¹⁸³Foundation for Innovative New Diagnostics, Geneva, Switzerland. ¹⁸⁴Institute of Health Research Epidemiological Surveillance and Trainings (IRESSEF), Dakar, Senegal. ¹⁸⁵Universal Health Monitor, Bethesda, MD, USA. ¹⁸⁶University of Glasgow, Glasgow, UK. ¹⁸⁷King Saud Medical City, Ministry of Health and College of Medicine Alfaisal University, Riyadh, Saudi Arabia. ¹⁸⁸Amrita Institute of Medical Sciences, Kochi, India. ¹⁸⁹International Food Policy Research Institute, New Delhi, India. ¹⁹⁰Goldman Hine LLP, Toronto, Ontario, Canada. ¹⁹¹Department of Gastroenterology, University Hospital Center Rijekja, Rijekja, Croatia. ¹⁹²School of Medicine, University of Belgrade, Belgrade, Serbia. ¹⁹³MaREI Centre, Ryan Institute & School of Engineering, University of Galway, Galway, Ireland. ¹⁹⁴University of Saskatchewan, Saskatoon, Saskatchewan, Canada. ¹⁹⁵Queensland University of Technology, Brisbane, Queensland, Australia. ¹⁹⁶Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK. ¹⁹⁷Faculty of Medicine, Alexandria University, Alexandria, Egypt. ¹⁹⁸New York State Department of Health, Albany, NY, USA. ¹⁹⁹American University of Beirut, Beirut, Lebanon. ²⁰⁰Faith to Action Network, Nairobi, Kenya. ²⁰¹International University of Catalonia, Barcelona, Spain. ²⁰²IntraHealth International, Nairobi, Kenya. ²⁰³African Population and Health Research Center, Nairobi, Kenya. ²⁰⁴Africa Centers for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia. ²⁰⁵Masaryk University, Brno, Czech Republic. ²⁰⁶Institute of Hydromechanics, National Academy of Sciences of Ukraine, Kiev, Ukraine. ²⁰⁷Yale School of Medicine, New Haven, CT, USA. ²⁰⁸International Livestock Research Institute, Nairobi, Kenya. ²⁰⁹University Clinic of Gastroenterohepatology, Faculty of Medicine, University "Ss. Cyril and Methodius", Skopje, Republic of Macedonia. ²¹⁰University of Bergen, Bergen, Norway. ²¹¹College of Dentistry, Dar Al Uloom University, Riyadh, Saudi Arabia. ²¹²Congolese Foundation for Medical Research, Brazzaville, Republic of the Congo. ²¹³Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany. ²¹⁴Covid Action Group, World Health Network, Son, Norway. ²¹⁵Department of Infectious Diseases, Internal Medicine, School of Medicine, Marmara University, Istanbul, Turkey. ²¹⁶Effective Basic Services (eBASE) Africa, Bamenda, Cameroon. ²¹⁷University of Geneva, Institute of Global Health, Geneva, Switzerland. ²¹⁸Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands. ²¹⁹Wayne State University School of Medicine, Detroit, MI, USA. ²²⁰International Independent Expert on Health Systems, Managua, Nicaragua. ²²¹Tohoku University Graduate School of Medicine, Sendai, Japan. ²²²McGill School of Population and Global Health, Montreal, Quebec, Canada. ²²³Training for Health Equity Network: THEnet, New York City, NY, USA. ²²⁴Dalhousie University, Halifax, Nova Scotia, Canada. ²²⁵Drugs for Neglected Diseases initiative, Geneva, Switzerland. ²²⁶ifo Institute at the University of Munich, Munich, Germany. ²²⁷Two Oceans in Health, Santo Domingo, Dominican Republic. ²²⁸Vietnam One Health University Network (VOHUN), Hanoi University of Public Health (HUPH), Hanoi, Vietnam. ²²⁹Molinari Economic Institute, Paris, France. ²³⁰CIMA, UMI-IFAEI/CNRS, FCEyN, Universidad de Buenos Aires-UBA/CONICET, Buenos Aires, Argentina. ²³¹National Health Care for the Homeless Council, Nashville, TN, USA. ²³²Chelsea and Westminster Hospital, London, UK. ²³³INFIQC-CONICET, National University of Córdoba, Córdoba, Argentina. ²³⁴Department of Botany, University of Chakwal, Chakwal, Pakistan. ²³⁵Brown University, Providence, RI, USA. ²³⁶Institute for Global Health and Development, Bissau, Guinea-Bissau. ²³⁷NHS Greater Glasgow and Clyde, Glasgow, UK. ²³⁸Erasmus University Medical Center, Rotterdam, The Netherlands. ²³⁹Africa Europe Foundation, Brussels, Belgium. ²⁴⁰Norwegian Institute of Public Health, Oslo, Norway. ²⁴¹Kohelet Policy Forum, Jerusalem, Israel. ²⁴²Chulalongkorn University, Bangkok, Thailand. ²⁴³Research Institute of Virology under the Ministry of Health of Uzbekistan, Tashkent, Uzbekistan. ²⁴⁴Child Health Research Foundation, Dhaka, Bangladesh. ²⁴⁵National Institute of Public Health, Mexico City, Mexico. ²⁴⁶Center of Molecular Immunology, La Havana, Cuba. ²⁴⁷University of Maryland, College Park, MD, USA. ²⁴⁸Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar. ²⁴⁹Technical University of Dortmund, Dortmund, Germany. ²⁵⁰University of California San Diego, San Diego, CA, USA. ²⁵¹Infectious Disease Department, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey. ²⁵²Faculty of Medicine, Syrian Private University, Damascus, Syrian Arab Republic. ²⁵³Department of Psychiatry, Jawahar Lal Nehru Memorial Hospital, Srinagar, India. ²⁵⁴Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia. ²⁵⁵The Office of the Government of the Republic of Lithuania, Vilnius, Lithuania. ²⁵⁶CORE Group Polio Project India, Delhi, India. ²⁵⁷Independent Consultant, Quito, Ecuador. ²⁵⁸Institute of Experimental Psychology, Centre of Social and Psychological Sciences, Slovak Academy of Sciences, Bratislava, Slovakia. ²⁵⁹Dublin City University, Dublin, Ireland. ²⁶⁰University of Calgary, Calgary, Alberta, Canada. ²⁶¹Institute for Research, Development and Innovation, International Medical University, Kuala Lumpur, Malaysia. ²⁶²Department of Health, Melbourne, Victoria, Australia. ²⁶³Norwegian University of Science and Technology, Trondheim, Norway. ²⁶⁴Faculty of Medicine, Aleppo University, Aleppo, Syrian Arab Republic. ²⁶⁵Global Health Literacy Academy, Risskov, Denmark. ²⁶⁶African Union, Addis Ababa, Ethiopia. ²⁶⁷University of British Columbia, Vancouver, British Columbia, Canada. ²⁶⁸Swiss Academies of Arts and Sciences, Bern, Switzerland. ²⁶⁹Indraprastha Institute of Information Technology, Delhi, India. ²⁷⁰Centre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya. ²⁷¹Burnet Institute Myanmar, Yangon, Myanmar. ²⁷²Institute for Health Sciences Research (CNRST/IRSS), Nanoro, Burkina Faso. ²⁷³People's Health Movement, Abomey-Calavi, Benin. ²⁷⁴Fundacion Octaedro, Quito, Ecuador. ²⁷⁵Khesar Gyalpo University of Medical Sciences of Bhutan, Thimphu, Bhutan. ²⁷⁶Antioquia University, Medellin, Colombia. ²⁷⁷Mälardalens University, Mälardalens, Sweden. ²⁷⁸Technical University of Denmark, Kongens Lyngby, Denmark. ²⁷⁹University of Michigan Medical School, Ann Arbor, MI, USA. ²⁸⁰Hospital Clínic, University of Barcelona, Barcelona, Spain. ²⁸¹Bruegel Free University of Brussels, Brussels, Belgium. ²⁸²College of Environmental Sciences and Engineering, Peking University, Beijing, China. ²⁸³University of Bath, Bath, UK. ²⁸⁴African Forum for Research and Education in Health, Kumasi, Ghana. ²⁸⁵National Centre for Infectious Diseases, Singapore, Singapore. ²⁸⁶Goberna Consulting Firm, Lima, Peru. ²⁸⁷Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.

Methods

Delphi expert panel member sample

We used an iterative sampling approach to generate a large panel for this Delphi study (Fig. 1). The four co-chairs (J.V.L., A.B., A.K. and A.E.-M.) identified a core group of 40 academic, health, NGO, government and policy experts from 25 countries and territories. Selection by the co-chairs was primarily based on publication record and engagement on COVID-19 issues as well as online biographies. Twenty-nine of these experts were well known to the chairs while seven were suggested through snowball sampling to result in geographical and gender equity among the core group of 40. Furthermore, a concerted effort was made towards multidisciplinary representation in the core group, including medical sciences (such as infectious diseases, public health and vaccinology), engineering, and social sciences (such as policy, law and ethics). The core group proposed additional experts to create a global panel of approximately 400 experts. The lead chair (J.V.L.) and methodologist (D.R.) led this core group through implementation of the project. Snowball sampling was then used as core group members identified individuals with expertise in COVID-19 from their professional networks to generate an initial list of potential Delphi panel members with the goal of broad representation. In proposing experts, co-chairs focused on identifying at least one representative from at least 100 countries. One co-chair (J.V.L.) took responsibility for reviewing the suggestions, with support from a research assistant who shared recent publications and a professional biography for every proposed co-author. Many initial suggestions were of leading experts with whom the co-chairs had previously collaborated.

The core group then reviewed the panel list for under-represented countries and PubMed/Medline searches were conducted using the search term 'COVID-19' in combination with the names of under-represented countries to identify authors of COVID-19 research studies involving primary data collection in these countries. Authors of relevant studies were invited to participate in the Delphi panel to further increase geographical diversity and include panellists beyond the core team members' networks. All of the panel participants were carefully vetted; most had published in one or more relevant fields.

To further validate the expertise of the panel, the study was described to the invitees ($n = 696$) with the following instructions: "If you consider your professional training and expertise applicable to the subject matter of this global consensus statement project, we encourage you to participate in the panel." Informed consent was obtained for each panellist after explaining the purpose of the study and their expected contributions, including review and approval of the submitted manuscript, by accession to the Round 1 (R1) survey. Our objective was for invited participants to explicitly consider whether they had the necessary level of expertise before joining the Delphi panel. We do not have specific information regarding the basis of invitees' non-participation but expect that these instructions enabled a substantial portion of non-respondents to self-select out of the study. We know that 84 invitees began the R1 survey but did not complete it; thus, if we assume that they did consider themselves to be eligible to participate but then decided not to do so, that would result in an estimated response rate of 82.1% (386 out of 470). The resultant expert panel is diverse in terms of demographic, disciplinary and geographical characteristics (Table 1).

Delphi statement domains

The core group reviewed the published literature available up to January 2022 to draft initial statements for the first Delphi survey round, grouped in the following domains: (1) communication; (2) health systems; (3) vaccination; (4) prevention; (5) treatment and care; and (6) pandemic inequities. No formal systematic review with stringent criteria for levels of evidence was performed owing to the sheer volume of COVID-19-related published studies and the frequency at which they were and continue to be published. However, all of the authors

and panellists were invited to suggest relevant papers, which were reviewed by the core group members based on journal rankings, paper citations and other metrics. In R1, panellists considered draft consensus statements based on the literature before moving to the next step of recommendations in round two (R2), which emanated from the panellists' feedback on the statements as well as new research findings over the course of data collection from 18 February 2022 to 28 April 2022.

Delphi method data collection

The study design consisted of digital data collection: two survey rounds (R1 and R2) of draft statements; an online consensus meeting of the core group (16 March 2022) to discuss salient issues; one round of draft recommendations (in R2); and, a final, third survey round (R3) of the consensus statements and recommendations (Fig. 1). The core group decided a priori to use a supermajority (that is, $\geq 67\%$ combined agreement) minimum cut-off for consensus. This more demanding cut-off (relative to a simple majority of greater than 50%) was considered to be necessary given the project goal of supporting global policy and programmatic actions to address the COVID-19 public health crisis. We used the QualtricsXM platform to develop and distribute the surveys (round duration ranged from 1.5 to 3 weeks) with four-point Likert-type categories for measuring the level of agreement with the statements and recommendations (that is, agree, somewhat agree, somewhat disagree, disagree); a fifth 'not qualified to respond' option was provided given the panel's range of COVID-19 expertise. Panellists could provide comments and suggest edits to individual statements and recommendations in text boxes, which followed each of the statements and recommendations. All rounds allowed for overall comments at the end of the survey, and the researchers reviewed 1,409, 755, and 188 comments associated with the statements in R1, R2 and R3, respectively, and 1,025 and 2,156 comments associated with the recommendations in R2 and R3, respectively. Summaries of changes based on panellist input from a previous round were available in text boxes next to each statement and recommendation in the subsequent round. Similarly, the definition for "Ending COVID-19 as a public health threat as evidenced by the resumption of social, cultural, religious, political, healthcare, economic and educational activities in each country's context" was presented during each round so that panellists could respond to statements on the basis of a shared understanding of how the phrase "ending COVID-19 as a public health threat" was defined for the purpose of this study. In R3, panellists also ranked the top half of recommendations within each of the six domains, which were automatically randomized to mitigate order-effect bias. Using Microsoft Excel (v.16), scores were calculated and normalized using the Dowdall system to compare rankings across domains by accounting for weighting bias due to differences in the total number of recommendations in each domain^{137,138}.

An important component of the data-collection process involves the discussion among core group members of issues that emerge from the early survey rounds and how best to incorporate such feedback in subsequent rounds. Given the geographical distribution of panel members and COVID-19-related travel and health concerns, we convened the core group virtually for in-depth, real-time deliberation. This web-based approach is different from in-person discussion of complicated or contentious issues; however, panel members had multiple opportunities to provide open-ended comments in the absence of dominant voices that can inhibit the expression of minority viewpoints during in-person convenings. Thus, the combination of real-time feedback (from core group members) and written feedback (from the entire panel) probably resulted in more comprehensive contributions overall.

Delphi data analysis

Data analysis reflected the multiple-methods nature of Delphi studies and was managed by an analytic team of core group members, the study methodologist and research assistants. Across the three rounds, we ran frequencies of all statements and recommendations (Supplementary

Discussion 2); the proportion who selected 'not qualified to respond' is reported in the data tables but removed from the denominator to calculate levels of agreement/disagreement from the relevant sample. The team then analysed the extensive qualitative data (that is, open-ended text-box comments). Specifically, comments were first reviewed individually by at least three core group members (J.V.L., co-chair; D.R., methodologist; and C.J.K.) and an additional co-author (T.M.W.). For each data collection round, comments were then discussed in online review meetings, including at least three core group members and an additional co-author. After review and discussion, comment suggestions were incorporated into statement and recommendation revisions for subsequent rounds. A supermajority of core group members (28 out of 40; 70%) participated in the online consensus meeting, which permitted in-depth breakout-group discussions on salient issues from R1 and R2 informing R3 revisions (Supplementary Discussion 3). Quantitative analysis of the final R3 results involved assigning each statement and recommendation a grade to indicate the level of combined agreement (agree + somewhat agree), using a system that has been used in other Delphi studies^{139–141} in which 'U' denotes unanimous (100%) agreement; 'A' denotes 90%–99% agreement; 'B' denotes 78%–89% agreement; and 'C' denotes 67%–77% agreement. Although all statements and recommendations exceeded the standard supermajority minimum of $\geq 67\%$ combined agreement for consensus, we highlighted those with $< 67\%$ for 'agree' alone for further analysis. Statements and recommendations were analysed using Fisher's exact tests in Stata (v.16) to assess differences in agreement by the following panellist characteristics: income level (high income versus low- and middle-income) for country of birth and country where currently working, primary sector of employment and primary field of employment (Supplementary Discussion 2). The use of the terms combined agreement and combined disagreement are presented in the results.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Additional data will be shared on request from the corresponding author for fair use.

137. Reilly, B. Social choice in the south seas: electoral innovation and the Borda count in the Pacific Island countries. *Int. Polit. Sci. Rev.* **23**, 355–372 (2016).
138. Fraenkel, J. & Grofman, B. The Borda count and its real-world alternatives: comparing scoring rules in Nauru and Slovenia. *Aust. J. Polit. Sci.* **49**, 186–205 (2014).
139. Rubino, F. et al. Joint international consensus statement for ending stigma of obesity. *Nat. Med.* **26**, 485–497 (2020).
140. Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat. Rev. Gastroenterol. Hepatol.* **19**, 60–78 (2021).
141. Lazarus, J. V. et al. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. *Nat. Commun.* **12**, 4450 (2021).

Acknowledgements The chairs and core author group thank all of the panellists who completed the surveys, including for their thousands of helpful comments. They specifically thank the few panellists who are not co-authors but did actively participate in the survey rounds: K. Adolf, N. Alwan, I. Araújo, M. Brookman-Amisshah, C. Caceres, M. Childs, S. Duckett, F. Farzadfar, A. Glassman, H. Hopkins, M. Kall, M. Paule Kiemy, M. Malebona Precious, K. Prather, V. Priesemann, P. Ananth Tambyah, K. Yaw and S. Zhan. They further thank ISGlobal research assistants L. van Selm, C. Pujol Martínez and R. Freiheit for support, and L. Ansley Hobbs (CUNY SPH) for technical support with the QualtricsXM platform. J.V.L., Q.B., A.L.G.-B., G.F., M.K., D.N., R.V. and T.M.W. acknowledge support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the "Centro de Excelencia Severo Ochoa 2019–2023" Programme (CEX2018-000806-S), and from the Government of Catalonia, Spain, through the CERCA Programme. J.S. acknowledges support from J. Waller for his contributions. No funding

was received for this manuscript. We thank Wilton Park for hosting and sponsoring the virtual consensus meeting on 16 March 2022.

Author contributions This study was led by four co-chairs (J.V.L., A.B., A.K. and A.E.-M.) who were part of a core group of 40 co-authors (J.V.L., D.R., C.J.K., S.A.K., L.J.A.R., G.A., R.B.L., J.A.B., M.L.B., Y.B.-Y., Q.B., C.B., M.B., S.-T.C., C.d.R., G.J.D., G.G., L.O.G., M.H., J.L.J., C.K., N.L., M.M., M.M.K., S.N., M.O.B., B.P., O.P., K.R., S.R., S.R., M.R., R.S., S.S., M.T.-H., S.V., P.Y., A.B., A.K. and A.E.-M.). The co-chairs regularly updated the core group members by email and J.V.L. led an online consensus meeting hosted by Wilton Park in March 2022. D.R., the lead chair (J.V.L.) and T.M.W. led the methodology. J.V.L., D.R., T.M.W. and C.J.K. reviewed all comments submitted as part of the three survey rounds. J.V.L., C.J.K. and T.M.W. reviewed all comments sent directly by email. J.V.L., D.R., C.J.K., T.M.W. and K.R. reviewed all comments from the peer reviewers. All COVID-19 Consensus Statement Panel members had the opportunity to review the full draft of the manuscript and provide three rounds of comments through QualtricsXM. Those fulfilling authorship criteria are named ($n=364$).

Competing interests J.V.L. reports research grants to his institution from AbbVie, Gilead Sciences and MSD, and speaker fees from AbbVie, Gilead Sciences, Intercept, Janssen, MSD and ViiV, and an advisory board fee from AbbVie and Novavax, all unrelated to this work. R.A. is a co-chair of the Occupational Medicine Committee of the British Medical Association and a member of the Industrial Injuries Advisory Council (UK). S.A. reports honoraria for lectures and educational events from Gilead, AbbVie, MSD and Biogen, and reports grants, not related to COVID-19, from Gilead and AbbVie. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary, Synairgen and Pfizer. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen and AstraZeneca. A.G.-S. is listed as an inventor on patents and patent applications (US patent numbers: 5,820,871; 5,854,037; 6,001,634; 6,146,642; 6,451,323; 6,468,544; 6,544,785; 6,573,079; 6,635,416; 6,649,372; 6,669,943; 6,740,519; 6,852,522; 6,866,853; 6,884,414; 6,887,699; 7,060,430; 7,384,774; 7,442,379; 7,494, 808; 7,588,768; 7,833,774; 8,012,490; 8,057,803; 8,124,101; 8,137,676; 8,591,881; 8,629,283; 8,673,314; 8,709,442; 8,709,730; 8,765,139; 8,828,406; 8,999,352; 9,051,359; 9,096,585; 9,175,069; 9,217,136; 9,217,157; 9,238,851; 9,352,033; 9,371,366; 9,387,240; 9,387,242; 9,549,975; 9,701,723; 9,708,373; 9,849,172; 9,908,930; 9,968,670; 10,035,984; 10,098,945; 10,131,695; 10,137,189; 10,179,806; 10,251,922; 10,308,913; 10,543,268; 10,544,207; 10,583,188; 10,736,956; 11,254,733; and 11,266,734) on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. S.G. reports being a member of Independent SAGE and member of the Pfizer Antivirals Advisory Board. P.H. reports being co-inventor of a COVID-19 recombinant protein vaccine technology owned by the Baylor College of Medicine (BCM) that was recently licenced by BCM non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The co-inventors have no involvement in licence negotiations conducted by the BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries that result in a commercial licence, a share of any royalty income. To date, BCM has not distributed any royalty income to the co-inventors on the COVID-19 recombinant protein vaccine technology. Any such distribution will be undertaken in accordance with BCM policy. A.K. has served as a paid consultant to the Independent Panel on Pandemic Preparedness and Response in 2020–21. K.K. is Chair of the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergencies (SAGE) and Member of SAGE. J.L. reports owning equity in Codiak BioSciences and Exocure Biosciences, both having developed experimental COVID-19 vaccines. G.M. reports honoraria for a presentation from Novartis and consulting fees from AstraZeneca. S.M. reports being founder and chief scientific officer of PulmoBioMed. T.S. serves as the scientific director of the O'Brien Institute for Public Health and reports funding from the Canadian Institutes of Health Research. V.S. is a member of the National Scientific Committee of Experts for COVID-19 in Greece and reports grants from Gilead and Abbvie that are not related to this work or to COVID-19 research. A.T. reports grants from the Foundation for Advancing Family Medicine Janus Research Grant; Canadian Frailty Network Research Grant, Speaking Honoraria: University of Ottawa, McMaster University, Northern Ontario School of Medicine, McGill University, University of Calgary, BC Bereavement Hotline, Early Education Teachers of Ontario-Yok Region Union, Ontario Council for Cooperation, TELUS Science World-Vancouver. R.B. has been COVID-19 adviser to UK government and acts as a senior scientific adviser for a communications company working for the UK Government on COVID-19. A.W. reports research funding from Pfizer (unrelated to COVID-19) and a consulting fee from Ocugen. K.Y. is an unpaid member of the Independent SAGE group of scientists. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-022-05398-2>.

Correspondence and requests for materials should be addressed to Jeffrey V. Lazarus.

Peer review information Nature thanks Jeremy Farrar, Sean Grant and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.



Health systems

1. Pandemic preparedness and response planning should adopt a whole-of-society approach that includes multiple disciplines, sectors, and actors (e.g., business, civil society, engineering, faith communities, mathematical modelling, military, media, psychology). Preparedness and response strategies should adopt whole-of-government approaches (e.g., multi-ministry coordination) to identify, review, and address resilience in health systems.
2. Governments should remove economic barriers to SARS-CoV-2 tests, personal protective equipment, treatments, and care.
3. To reduce the burden on hospitals, primary care should be strengthened to include testing, contact tracing, the monitoring of mild symptoms, and vaccination.
4. Healthcare organisations should support their workers' physical, mental and social well-being.
5. Governments and global health organisations should support the development of regional hubs for the manufacturing of COVID-19 supplies, treatments, and vaccines.
6. Public health policy should take better account of the potential long-term impact of the unchecked spread of COVID-19, given ongoing uncertainties about the prevalence, severity, and duration of post-COVID-19 morbidity ("Long COVID").
7. Because the global marketplace has not satisfied demand for vaccines, treatments and supplies, countries and regions should consider legislative and regulatory reforms to address these market failures (e.g., nationalising manufacturing capacity, negotiating global and regional trade agreements, adjusting intra-country intellectual property rights).
8. In the absence of a new multilateral organisation focused on pandemic control, Member States should authorise WHO to lead a large, inclusive, multi-stakeholder, global effort to provide public health and clinical targets pertaining to the pandemic, with an emphasis on cases, vaccination, morbidity and mortality.



Prevention

1. All countries should adopt a "vaccines plus" approach that includes a combination of COVID-19 vaccination, prevention measures, treatment and financial incentives.
2. Prevention of SARS-CoV-2 transmission in the workplace, educational institutions and centres of commerce should remain a high priority, reflected in public health guidance and supported through multiple social measures and structural interventions (e.g., remote work/schooling policies, ventilation, air filtration, facemask wearing).
3. Governments should regulate and incentivise the development and deployment of structural prevention measures (e.g., ventilation, air filtration) to mitigate airborne transmission of SARS-CoV-2, with an early emphasis on high-risk settings.

Priority recommendations to end COVID-19 as a public health threat



Communication

1. Community leaders, scientific experts, and public health authorities should collaborate to develop public health messages that build and enhance individual and community trust and utilise the preferred means of access and communication for different populations.
2. Public health authorities should partner with individuals and organisations that are trusted within their communities to provide accurate, accessible information about the pandemic and inform behaviour change.
3. Public health professionals and authorities should combat false information proactively based on clear, direct, culturally-responsive messaging that is free of unnecessary scientific jargon.
4. Institutions and individuals that wish to advance public trust should: (i) draw on evidence about how trust is created and restored; (ii) provide training and professional development emphasising skills and competencies that convey trustworthiness; and (iii) develop, implement, and assess communication strategies that are highly likely to create or restore trust.
5. Governments should determine which agencies are or should be accountable for monitoring health information and develop monitoring tools to identify false information.



Pandemic inequities

1. Pandemic preparedness and response should address pre-existing social and health inequities.
2. Global trade and health organisations should coordinate with countries to negotiate the transfer of technologies enabling manufacturers in low- and middle-income countries to develop quality assured and affordable vaccines, tests, and therapeutics.
3. Recognising that local and regional contexts are important for equitable responses to the pandemic, governments should engage communities and multidisciplinary experts who understand the local context when developing operational plans for ending COVID-19 as a public health threat.
4. In addition to current vaccine equity efforts, governments and global health organisations should better coordinate to make COVID-19 tests and treatments affordable for all people in all countries.
5. High-income countries should refocus the distribution of vaccines to countries with low rates of vaccination and inadequate access to vaccines.



Treatment and care

1. Promote multi-sectoral collaboration to accelerate the development of new therapies for all stages of COVID-19 (e.g., outpatient, hospitalisation and Long COVID).
2. Prioritise research funding for Long COVID to develop diagnostic tools, treatment and care, and knowledge about extrinsic factors (e.g., stigma and discrimination).
3. Global case definitions for SARS-CoV-2 and for COVID-19 morbidity and mortality should be standardised.



Vaccination

1. Government, philanthropic and industry funding should include a focus on developing vaccines that provide long-lasting protection against multiple SARS-CoV-2 variants.
2. In settings where individuals have lower levels of trust in government, vaccination efforts should engage trusted local leaders and organisations.
3. Vaccination messaging should clearly explain the efficacy and limitations of current vaccines in preventing SARS-CoV-2 transmission and reducing the severity of COVID-19.

Extended Data Fig. 1 | Top half of the ranking of the recommendations in each domain. In the third and final round of the Delphi process, panel members were asked to rank the recommendations per domain (n = 6) based on importance.

This figure shows the top half of the recommendations for each of the six domains (communication; health systems; vaccination; prevention; treatment and care; and inequities).

Extended Data Table 1 | Recommendations with 5% or greater disagreement

REC3.6 (18% SD/D)	As the causes of vaccine hesitancy are not solely a function of information or worldview, economic incentives should be considered in parallel with information and access to increase vaccination rates.
REC2.18 (11% SD/D)	In settings where access to polymerase chain reaction (PCR) or antigen tests may be limited, providers should consider adopting a syndromic approach to COVID-19 diagnosis for symptomatic individuals.
REC2.17 (8% SD/D)	In the absence of a new multilateral organisation focused on pandemic control, Member States should authorise WHO to lead a large, inclusive, multi-stakeholder, global effort to provide public health and clinical targets pertaining to the pandemic, with an emphasis on cases, vaccination, morbidity and mortality.
REC4.7 (8% SD/D)	Governments should only consider imposing broad restrictions on civil liberties in the event of variants of concern presenting risk of high rates of transmission and severity, coupled with (i) waning immunity or (ii) vaccine resistance.
REC1.10 (7% SD/D)	Governments should consider holding publishers of false health information liable, while balancing civil liberties.
REC2.16 (7% SD/D)	Because the global marketplace has not satisfied demand for vaccines, treatments and supplies, countries and regions should consider legislative and regulatory reforms to address these market failures (e.g., nationalising manufacturing capacity, negotiating global and regional trade agreements, adjusting intra-country intellectual property rights).

Across the study, only six recommendations evidenced 5% or greater disagreement (combined "somewhat disagree/disagree") among the 386 panellists. Areas of disagreement broadly included socio-political and socio-cultural considerations that vary among countries, geopolitical concerns that may impact public health guidance and distinct medical points of view.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a | Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	We report proportion of participants selecting "man", "woman", "non-binary or gender diverse", and "prefer not to say". As neither sex nor gender are determinative of one's subject matter expertise (the primary inclusion criteria for the panel), we did not consider any tests to investigate differences in this expertise by gender. Sex was not collected. The panel reported near-gender parity between men and women.
Population characteristics	<p>The panel's characteristics are reported in Table 4 and are as follows:</p> <p>Gender: Man (58%), Woman (40%), No response (2%)</p> <p>Primary sector of employment: Civil Society (66%), Private (16%), Academic (10%), Public (5%), Other (2%), No response (1%)</p> <p>Primary field of employment: Public Health (41%), Clinical Research/Care (24%), Health Policy/Advocacy (17%), Basic/Physical/Mathematical Sciences (11%), Other (6%), No response (2%)</p> <p>Country income level: Low or middle income country (50%), High income country (48%), No response (1%)</p> <p>Global region of origin: Europe & Central Asia (30%), Latin America & Caribbean (15%), East Asia & Pacific (13%), North America (12%), Sub-Saharan Africa (11%), Middle East & North Africa (9%), South Asia (9%)</p>
Recruitment	We employed an iterative sampling approach to generate a large panel for this Delphi study (Figure 1). The four co-chairs (JVL, AB, AK, AE-M) identified a core group of 40 experts from 25 countries, representing discipline, geographic and gender diversity to guide development of consensus statements and recommendations to end COVID-19 as a public health threat. The lead chair (JVL) and methodologist (DR) led this core group through implementation of the project. Snowball sampling was then used as core group members identified individuals with expertise in COVID-19 from their professional networks to generate an initial list of potential Delphi panel members with the goal of broad representation. The core group reviewed the panel list for under-represented countries and PubMed/Medline searches were conducted using the search term "COVID-19" in combination with the names of under-represented countries to identify authors of COVID-19 research studies involving primary data collection in these countries. Authors of relevant studies were invited to participate in the Delphi panel in order to further increase geographic diversity and include panellists beyond the core team members' networks. To further validate the expertise of the panel, the study was described to the invitees, who were instructed not to participate if they considered themselves lacking the necessary level of expertise. Informed consent was obtained for each panellist after explaining the purpose of the study and their expected contributions, including review and approval of the submitted manuscript, by accession to the R1 survey.
Ethics oversight	This study has been exempted from ethical review by the Research Ethics Committee of the Hospital Clinic, University of Barcelona, Spain.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	This is a three-round, standard Delphi consensus statement study.
Research sample	Selection of participants was primarily based on publication record and engagement on the issues, not necessarily to be representative of any country, sector, or field. A number of these experts were well known to the chairs while others were suggested through snowball sampling to ensure broad international geographic and gender equity among the core group of 40. Further, a concerted effort was made to ensure multi-disciplinary representation in the core group, including medical sciences (e.g., infectious diseases, and public health, vaccinology), engineering, and social sciences (e.g., policy, law, ethics). It was a prerequisite that the core group would be able to suggest additional experts to create the global panel of 386 experts (58% male, 66% working primarily in civil society, 41% working primarily in public health, and 50% working in low and middle income countries).
Sampling strategy	We employed an iterative sampling approach via a core group of 40 public health experts that represented gender and geographic

Sampling strategy	parity in order to create a robust international multi-disciplinary panel that could substantively engage with the content of the study.
Data collection	We used the QualtricsXM® platform to develop and distribute the surveys (round duration ranged from 1.5 to 3 weeks) with 4-point Likert-type categories for measuring level of agreement with the statements and recommendations (i.e., Agree, Somewhat agree, Somewhat disagree, Disagree); a fifth 'not qualified to respond' option was provided given the panel's range of COVID-19 expertise. Panellists could provide comments and suggest edits to individual statements and recommendations in text boxes, which followed each of the statements and recommendations.
Timing	The study design consisted of digital data collection: two survey rounds (R1 and R2) of draft statements and recommendations (18 February-15 March 2022); an online consensus meeting of the core group (16 March 2022); and a third survey round (R3) (15 April-28 April 2022).
Data exclusions	No data were excluded.
Non-participation	All co-authors participated in the Delphi process and approved the submitted consensus statement manuscript.
Randomization	Panelists participated as a single group. However, when ranking the recommendations, the recommendation items were randomized within each domain so as to avoid question-order bias.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging